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3ABSTRACT
Background:  Neurodegenerative  diseases  are  diseases  of  the  nervous  system 
with  progressive  course  leading  to  death.  Treatment  remains  symptomatic. 
Development of neuroprotective agents has been hampered for various reasons. 
This includes the inability of making the diagnosis accurately early in the course 
and  the  lack  of  reliable  disease  progression  markers  which  could  be  used  in 
future treatment trials.
Transcranial magnetic stimulation (TMS) is a non-invasive and pain-free method 
for assessment of brain function.
Methods:  Here  we  evaluated  TMS  and  its  potential  of  serving  as  reliable 
biomarker for neurodegenerative diseases with genetic cause.
After  clinical  delineation  of our  patient  cohorts  with  Huntington’s  chorea  and 
young-onset  Parkin-related  Parkinsonism,  we  enrolled  both  patients  as  well  as 
asymptomatic/ presymptomatic gene-carriers.  Patients, carriers and age-matched 
healthy  controls  were  studied  using  TMS  to  establish  an  electrophysiological 
footprint of these conditions.
Results:  We found abnormalities in electrophysiological parameters which were 
present in manifesting patients and/or non-manifesting gene mutation carriers.
In  HD,  both  presymptomatic  and  early  manifest  patients  had  increased  resting 
and active motor cortex thresholds.  Short afferent inhibition (SAI), a measure of 
sensory-motor  integration,  was  reduced  in  manifesting  patients  only.  SAI 
changes were inversely correlated with clinical parameters like predicted years to 
onset and UHDRS motor score.
4Abnormalities  in  Parkin  patients  included  prolonged  central  motor  conduction 
time  (CMCT),  while  thresholds  and  cortical  inhibitory  activity  were  normal. 
Asymptomatic  carriers  had increased motor thresholds  and abnormal  inhibitory 
measures (SICI recruitment) while CMCT was normal.
Conclusion:  We  conclude  that  TMS  may  be  a  potential  biomarker  for 
neurodegenerative  genetic  diseases  1)  to  detect  changes  early  in  the  disease 
course  and  to  monitor  disease  progression;  2)  to  help  differentiating  between 
clinically  similar  diseases  on  the  basis  of certain  electrophysiological  patterns; 
and 3)  to give  insight into underlying mechanisms of the disorders studied.  Our 
findings suggest the potential for future research.
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18V.  Thesis Overview
Chapter  1   will introduce the topic of neurodegenerative disease. The concept of 
biomarkers  as  a  measure  of disease  progression  and  their  importance  towards 
identification  of neuroprotective  agents  will  be  discussed.  The  terms  ‘mode  of 
inheritance’,  ‘penetrance’,  ‘manifesting’ and ‘non-manifesting carriers’  and ‘pre­
symptomatic  gene carriers’  are  introduced.  The  idea  (and  hypotheses)  of using 
transcranial magnetic stimulation as a possible biomarker is formulated.
Chapter 2  provides  a review  of the  diseases  studied here,  Huntington’s disease 
and Parkin-related Parkinsonism.
Chapter  3 entails  the  clinical  experiments.  A  clinical delineation  of  these
conditions, their phenocopies and related syndromes are discussed.
Chapter  4  introduces  the  technique  of  transcranial  magnetic  stimulation,  the 
method used for the experiments described in this thesis.
Chapter  5 presents  a  literature  review  on  the  use  of transcranial  magnetic
stimulation in the patient groups of interest and related disorders; in other words, 
a literature review on TMS in genetic movement disorders.
Chapter  6 describes  the  methods  of  the  performed experiments:  subject
ascertainment, electrophysiological parameters and methods of data analysis.
Chapter 7 presents the results of the TMS experiment in Huntington’s disease.
Chapter 8 presents the results of the TMS experiment in Parkin disease.
Chapter 9 delivers a discussion of the findings in  view  of the  hypothesis of the 
thesis and in context of findings from other research groups.
19Chapter  10 delivers a conclusion. Suggestions are being made in which direction 
future work could go.
20B)  Thesis
Chapter 1
I.  Neurodegenerative Disease and the concept of biomarkers
The  term  “neurodegeneration”  originates  from  the  Greek  word veupo-,  neuro-, 
"nerval" and the Latin word degenerare, "to decline" or "to worsen" and refers to 
conditions  characterized  by  progressive  dysfunction  of  the  nervous  system. 
Figure 1.1  demonstrates the time course of neurodegemative diseases.
Figure  1.1.  Natural  history  of a  neurodegenerative  disorder.  Over  time 
neuronal  survival  and  neuronal  function  declines  (disease  onset,  yellow 
line).  Eventually,  surviving  cells  cannot  compensate  for  longer,  clinical 
symptoms (red dotted  line) become overt (green vertical  line) and worsen 
in parallel to neuronal loss. A diagnosis may be made at a later stage (white 
vertical line).
Natural History of 
Neurodegenerative Disorder
Symptomatic Predin ical
21Atrophy of the affected central or peripheral nervous system structures are often 
associated. According to the function of the neurons lost, the sympomatology can 
vary  and may  include movement disorders or/and dementia or other functional 
systems.  Important  examples  of  neurodegenerative  diseases  are  Parkinson’s 
disease  and  Alzheimer’s  disease,  however,  the  list  of conditions  is  long.  Both 
hereditary and sporadic forms occur.
Treatment  of  neurodegenerative  diseases  is  difficult  and  often  remains 
unsatisfactory.  To  date,  only  symptomatic  treatments  are  available.  No proven 
treatments  that delay  the onset or prevent the progression of neurodegenerative 
diseases  have yet been discovered and it is a major scientific  and public  health 
goal to identify neuroprotective agents.
The  development  of treatments  has  been  hampered  by  three  challenges:  1)  the 
underlying mechanisms causing the progressive cell  loss remain ill  understood, 
2) the lack of tools for accurate ante-mortem diagnosis and 3) the lack of reliable 
disease  markers  to  monitor  disease  processes,  especially  in  earliest  disease 
stages.1
While elucidating disease mechanisms is not a prerequisite for the development 
of therapies,  testing  and  implementing  such  therapies  requires  identification  of 
appropriate  patient  populations,  especially  those  individuals  in  the  preclinical 
(asymptomatic) stages.1  For this, antecedent disease biomarkers (i.e., markers of 
neuropathologic  disease  in  the  absence  of  any  clinical  symptoms)  need  to  be 
identified and carefully characterized in order to test, challenge and validate any
22possible therapies capable of preventing or delaying the onset of neuronal death 
and consequent clinical presentation in the appropriate populations.
Clinically  useful  biomarkers  require  certain  characteristics.  They  should  be 
precise,  reliable  and reproducible.  Numerous potential  biomarkers are currently 
being explored, challenged and evaluated.
Pathological  markers  which  may  indicate  generalized  processes  or  even  those 
with  more  direct  relevance  to  the  specific  disease  (e.g.  Lewy  bodies  in 
Parkinson’s disease or AB and tau in Alzheimer’s disease) may not be clinically 
useful  for diagnosis  or monitoring during  life,  as  ascertaining brain  biopsies  is 
obviously limited because of the invasive nature.
In  inherited  disorders,  fragment  of DNA  sequences  that  causes  disease  or  are 
associated with susceptibility to disease can serve as genetic biomarkers (genetic 
marker,  e.g.  trinuleotid  repeat  in  Huntington’s  disease  or  mutations  or 
rearrangements  in  Parkin-related  parkinsonism).  Genetic  markers  may  help  to 
confirm the diagnosis in a patient and in some conditions may permit predictive 
testing  in  the  presymptomatic  phase.  Identification  of genetic  markers  are  also 
the gate to pathophysiological insights. However, genetic testing does not permit 
disease monitoring.
In this thesis the potential use of the electrophysiological technique, transcranial 
magnetic stimulation as a useful biomarker will be assessed and discussed in the 
following.
23II.  Introduction to Transcranial Magnetic Stimulation
Transcranial Magnetic Stimulation (TMS) is a non-invasive electrophysiological 
technique of stimulating cortical neurons which allows assessment of the central 
and  peripheral  nervous  system.  Since  its  development  by  Barker  in  1985,  a 
variety  of  TMS  paradigms  have  been  developed  and  intensively  investigated. 
This  includes  measures  of  cortico-cortical  connectivity,  cortico-spinal 
connectivity, both excitatory and inhibitory mechanisms, and plasticity.  Insights 
into  correlations  between TMS  measures  and  underlying  cellular  mechanisms, 
namely  which neurotransmitter may be involved,  have  been proposed based on 
pharmacological modifiability of TMS measures and previous neuropathological 
findings. Certain electrophysiological abnormalities or patterns may be indicative 
of distinct disorders.  Furthermore, correlations between TMS abnormalities and 
clinical  findings  (e.g.  severity  of overall  disease  or individual  symptoms)  have 
been explored for numerous diseases.
Thus, in view of the painfree and non-invasive character and the correlation with 
functional  systems and clinical  findings TMS represents an interesting potential 
biomarker for neurodegenerative disease.
III.  Mode of inheritance, penetrance and manifesting versus pre­
symptomatic/ non-manifesting subjects
In Mendelian genetics two forms of inheritance can be distinguished. Autosomal 
dominant  inheritance  is  characterized  by  alleles  that  express  themselves  at  the 
expense  of alternate  alleles,  thus  a  single  heterozygous  pathogenic  mutation  in 
one  of the  two alleles  is sufficient  to cause disease.  By contrast recessive traits
24are defined by the fact that expression of an allele is suppressed in the presence 
of  a  dominant  allele  and  thus  two  mutations  (either  the  same  mutation 
(homozygous)  or  two  different  changes  in  the  two  alleles  (compound 
heterozygous)) are needed for production of symptoms.
For  autosomal  dominant  conditions,  the  genetic  term  of  “penetrance”  also 
becomes interesting in the context of the proposed studies and is defined as the 
proportion of individuals carrying a particular variation of a gene (an allele) that 
also express a particular trait (the phenotype).  Full penetrance means that every 
individual  carrying a gene mutation will  develop symptoms eventually  whereas 
reduced  (or  incomplete)  penetrance  refers  to  conditions  where  not  every  gene 
carrier develops symptoms or signs. Reduced penetrance probably results from a 
combination of genetic, environmental, and lifestyle factors, many of which are 
unknown.  An  example  for a movement disorder with  high,  basically complete, 
penetrance  is  Huntington's disease.  On  the  other hand,  penetrance  is  relatively 
low  for  DYT1  dystonia.  Only  about  30%  of patients  carrying  a  mutation  will 
develop symptoms. Based on an age-dependency of manifestation of symptoms, 
one  can  be  reasonably  confident  that  so-called  “non-manifesting  DYT1  gene 
carriers” over the age of thirty will not manifest symptoms in the future and thus 
can be considered as truly different from manifesting gene carriers.2,3 Such non­
manifesting gene mutation carriers are of particular interest to researchers as they 
allow studying consequences of the mutated gene other than clinical symptoms.
With respect to recessive disorders, in recent years, several monogenic causes of 
disease have been identified. This includes parkinsonism where mutations can be 
detected  in  about  3%  of patients,  but  the  proportion  can  be  as  high  as  77%  in 
groups of patients selected for age  at onset,  positive family  history4,  and ethnic
25origin.5’6  Similarly  to  non-manifesting  gene  carriers  of  dominant  disorders, 
hetereozygous carriers of an autosomal recessive disease are of particular interest 
to  researchers.  These  subjects  carry  one  mutation,  which  -   as  defined  by  the 
recessive  inheritance  -   is  not  enough  to  produce  a  full  blown  phenotype. 
However,  there  has been increasing debate  whether and how the gene  mutation 
may  show  its  hand  and  whether  carriers  may  be  predisposed  to  developing 
clinical  symptoms  later in  life,  for example  idiopathic  Parkinson’s disease as  it 
has  been  reported  for  individual  cases  with  parkin-  or  PINK 1-related 
parkinsonism.7
Studying non-manifesting individuals may give insight into the pathophysiology 
of  the  disorder.  Studying  these  individuals  in  addition  to  patients  may 
furthermore  allow  challenging  the  method  (in  our  case  transcranial  magnetic 
stimulation) regarding its potential of monitoring disease processes, even in  the 
pre-clinical  phase.  We  have  thus chosen  to study clinically  affected patients  as 
well  as  non-affected  gene  mutation  carriers.  We  have  chosen  Huntington’s 
disease  as  an  example  of  autosomal  dominant  inheritance  and  Parkin-related 
parkinsonism as recessive disorder.
IV.  Aims and Hypotheses
We  had  two  main  aims.  Our  first  aim  was  to  clinically  delineate  genetic 
neurodegenerative  diseases.  Because  lumping  of  clinically  similar  conditions 
may  hamper  their  workup  (identification  of  genetic  causes  and  selection  of 
populations  for  future  therapeutic  trials),  delineation  of  these  disorders  is  an 
important first step.
26Our second aim was to use electrophysiological techniques to probe the function 
of the motor system in patients with genetic movement disorders. We applied the 
techniques  in  patients  with  clinical  disease  as  well  as  those  without  clinical 
symptoms,  for  the  reasons  outlined  above,  that  is  to  evaluate  the  potential 
usefulness of TMS as a biomarker.
We set out the following main hypotheses for our experiments:
1.  That  electrophysiological  abnormalities  present  in  the  studied  patients 
may give insight into the pathophysiology of disease.
2.  That  certain  TMS  parameters  may  be  useful  markers  to  differentiate 
between disorders, thus patients with distinct genetic disorders from those 
without (Mendelian) genetic mutations with a similar clinical presentation 
(sporadic disease) or those with a distinct other genetic disorder.
3.  That  non-manifesting/  premanifesting  gene  carriers  show 
electrophysiological  abnormalities  which  reflect  subtle  pre-clinical 
abnormalities  and  that  these  affect  similar  systems  to  those  seen  in 
manifesting gene carriers
4.  That  TMS  may  be  useful  to  measure  progression  of neurodegenerative 
diseases.
27Chapter 2  Clinical Delineation of Genetic Movement Disorders
I.  Huntington's disease -  an example of autosomal dominant 
inheritance
Huntington’s  disease  (HD),  a  neurodegenerative  autosomal  dominant  disorder 
due  to  mutation  of the  Huntingtin  gene  (IT15)  on  chromosome  48  is  the  most 
important cause of genetic chorea.  More precisely, HD is due to prolongation of 
a  physiological  polyglutamine  stretch  which  ranges  from  27  to  35  in  healthy. 
Penetrance is incomplete between 36 and 39 repeats and individuals may or may 
not develop disease. Ranges of 40 or more repeats eventually cause HD and the 
longer  the  stretch  the  more  severe  the  clinical  phenotype.  Disease  onset  is 
inversely related to the number of repeats. 9  10
The prevalence of HD has been found high in regions of Venezuela and Scotland 
and relatively  low  for Japan,  Finland and Norway.  1 1   12 In Europe and North
America the prevalence is about 4-8 per 100 000.
Onset of classic HD is around age 40 with a combination of personality changes, 
generalized chorea,  and cognitive decline.  However,  when affecting children or 
adolescents, HD tends to present as akinetic rigid variant (Westphal form) rather 
than with chorea. This young-onset variant is more commonly inherited from the 
father  due  to  meiotic  instability  with  an  increased  risk  of  expansion.  Other 
features  in  both  adult  and  young  onset  forms  include  eye  movement 
abnormalities  (impersistence  of gaze,  difficulty  initiating  saccades),  dysarthria, 
dysphagia,  pyramidal  signs  and ataxia resulting  in  walking with  imbalance  and 
reduced  postural  stability.  Dystonia,  myoclonus,  tics  and  tremor  are  also
28compatible  with  a  diagnosis  of HD.  Progression  is  inexorable  with  death  after 
15-20 years.
Brain  imaging reveals  progressive  atrophy  of the  caudate  nuclei,  present  years 
before onset of symptoms.
The diagnosis is based on genetic testing. Positive testing has major implications 
on the entire family and genetic counselling should be offered to explain risk of 
inheriting  the  disease  (50%)  and  penetrance  (100%  when  the  polyglutamine 
stretch exceeds 40 repeats).9
Therapy  remains  symptomatic.  Tetrabenazine  reduces  chorea  through 
presynaptic  dopamine  depletion  and  mild  D2-receptor  blockage.  Typical  and 
atypical  neuroleptics  also  reduce  chorea.  However,  chorea  is  usually  more 
bothersome for relatives and carers than for patients. Furthermore, if medication 
is  excessive,  motor  abilities  may  markedly  deteriorate  as  chorea  becomes 
replaced by disabling hypokinesia and bradykinesia,  hence, primary aim should 
be to lessen chorea rather than fully suppress it.
Depression can be treated with classical antidepressants.  Deep brain stimulation 
of the  globus  pallidus  intemus  has  been  reported to bring  temporary  benefit  in 
single case reports but can not stop neurodegeneration.1 3  Multiple drug trials are 
currently being carried out hoping to find neuroprotective agents.
The exact underlying mechanisms of HD are not fully understood.  Aggregation 
of  mutant  protein  fragments,  interference  with  transcription  factors  and  gene 
expression, abnormal  levels of nerve growth factors and calcium,  mitochondrial 
dysfunction,  reduction  of  synaptic  transmission  resulting  in  interference  of 
signaling pathways seem to play a role. 14  10  1 5
29II.  Parkin-related Parkinson’s disease - an example of autosomal 
recessive disease
Idiopathic  Parkinson’s  disease  is  characterized  by  the  triad  of  bradykinesia 
(fatiguing of repetitive movements), tremor and rigidity. Typically, age of onset 
is  in  late  adulthood,  however  young-onset  (onset  before  age  40)  and juvenile- 
onset forms occur. Whereas classic Parkinson’s disease is considered idiopathic, 
twenty percent of patients with young-onset Parkinson's disease have a positive 
family history in that at least one first- or second-degree relative in the same or 
antecedent generations was also affected by parkinsonism.  1 6
In recent years, several loci of parkinsonism with dominant (e.g. PARK8 related 
to  leucine-rich repeat kinase 2(LRRK2)) and recessive  (e.g.  PARK2 related to 
parkin4  or  PARK6  related  to  PTEN-induced  putative  kinase  1   (PINK1)7’17) 
inheritance have been discovered. Of these, parkin-related parkinsonism (OMIM 
602544)  is  the  most  common  cause  of  autosomal  recessive  “young-onset 
Parkinson’s  disease”  -   it  accounts  for approximately  half of the  familial  cases 
with disease onset before age 40 and for 75% in those with onset age 20 years or 
younger (juvenile PD).  On the other hand, parkin mutations are unlikely (<5%) 
in  patients  with  later  onset  (after  age  30  years).4  The  clinical  phenotype  is 
dominated  by  levodopa-responsive  parkinsonism  with  a  benign  course.
i   f t  i Q
Generally, the younger the age at onset the slower the evolution.  ’   Dystonia 
usually  affecting  the  lower  limbs  may  be  a  presenting  sign  in  up  to  40%.4 
Exercise-induced  dykinesia/dystonia  as  presenting  sign  of  parkin-related 
parkinsonism has also been described.2 1   Pyramidal  features in the form of brisk 
reflexes occur in  about half of the  patients.  However,  both  dystonia  at onset
30and  brisk  reflexes  may  not  be  a  consequence  of  the  presence  of  the  parkin 
mutation, but correlate better with the early onset age.*"0
Overall, no clear clinical  signs to distinguish idiopathic  Parkinson’s disease and 
parkin-related parkinsonism have  been  identified,  although one study  suggested 
that sense of smell may be preserved in parkin.23 However, neuropathologically, 
parkin  is  distinct from  idiopathic  Parkinson’s disease  where  Lewy  bodies are  a 
hallmark  feature.  In  parkin  Lewy  bodes  are  absent  or scarce24'* "6,  although  this
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remains matter of debate.“
Parkin  mutations  associated  with  PD  affect  all  exons,  and  include  point 
mutations,  small  insertions/deletions  and  much  larger  deletions,  and  exon 
duplications  and  triplications.29,30  Most  parkin31  patients  carry  two  different 
mutations  (compound  heterozygotes).  A  genotype-phenotype  analysis  of  146 
patients  with  and  250  patients  without  parkin  mutations,  suggested  disease 
severity  (as  measured  by  the  United  Parkinson's  Disease  Rating  Scale  motor 
score) may be greater in carriers of at least one missense mutation compared to 
those carrying two truncating mutations.20 The localization of the mutations also 
played  a  role;  missense  mutations  in  functional  domains  of parkin  resulted  in 
earlier onset. Patients with a single heterozygous mutation had significantly later 
and  more  asymmetrical  onset and more  frequent  levodopa-induced fluctuations 
and dystonia than patients with two mutations.20
The role of a single parkin mutation remains controversial and it is being debated
whether  asymptomatic  parkin  heterozygotes  (carriers)  are  predisposed  to
developing  (late-onset)  parkinsonism.  Cohort  studies  revealed  unequivocal
results.32,33  However,  it  has  been  shown  that  carriers  can  have  mild
extrapyramidal  signs and perhaps a susceptibility to behavioral disorder as  well
31as nigrostriatal dysfunction on functional imaging34,35 and discrete abnormalities 
on voxel-based morphometry36.
32Chapter 3  Clinical  Experiments  -   Clinical  delineation  of Huntington’s 
disease and Parkin-related young-onset Parkinson’s disease
During  patient  ascertainment for this  study,  we have encountered patients  (and 
families)  with  phenotypes  indistinguishable  from  or  similar  to  Huntington’s 
disease  and  Parkin-related parkinsonism.  However,  these  patients  turned out  to 
not  carry  the  relevant  gene  mutation.  This  prompted  a  detailed  work-up  with 
genetic analysis of such cases as well as a review paper. Some of these data will 
be presented in the following.
I.  Clinical delineation of Huntington’s disease
1.  Phenotypic homogeneity of the Huntington’s disease-like
presentation in a SCA17 family
The  family  of  a  50-year-old  Caucasian  woman37  carried  a  diagnosis  of 
Huntington’s  disease,  based  on clinical  details  of affected family  members  and 
results  of available  chromosome  4  haplotype  data  in  the  early  1990’s.  At  that 
time,  she  was  unaffected  and  was  counseled  as  having  a  low  risk  of  disease 
manifestation based on the linkage data.
She  developed  clinical  features  compatible  with  HD,  including  generalized 
chorea,  cognitive  and  behavioral  changes,  and eye  movement  abnormalities  at 
age 44. Genetic testing for an 7775/HD expansion carried out by us was negative. 
The  syndrome  affected  five  members  of  the  family  suggestive  of  autosomal 
dominant inheritance. Onset was around age 40 (range 37-45).
Because of additional  clinical  features other conditions including DRPLA  were
considered.  DRPLA  can  present  with  a  combination  of  chorea,  myoclonus,
cognitive  impairment,  and cerebellar ataxia.  However,  repeat expansions  in  the
33atrophin-1  gene  were  excluded.  Choreo-acanthocytosis  was  excluded  by 
peripheral  blood  smears.  Also,  inheritance  of classic  choreo-acanthocytosis  is 
usually  autosomal  recessive.  Among  the  HD-like  (HDL)  syndromes,  HDL1,  a 
familial  prion disease due to mutation in the PRNP gene,  is a more progressive 
disease  with  an  average  duration of  1   to  5  years.  HDL2,  caused by  dominant 
mutations  in  the junctophilin-3  gene,  has  not  been  reported  in  Caucasians.39 
HDL3  is  an  autosomal-recessive  condition  originally  described  in  a  Saudi- 
Arabian family.40 Finally,  HDL 4 or SCA17 can present with a clinical  picture 
indistinguishable  from classical  Huntington’s  disease  (also  see  section  Chapter 
3.1.2d).  This  has been documented in both heterozygous  and homozygous  TBP 
mutation  carriers,  although  most  of  these  patients  also  had  some  cerebellar
•__ „  41, 42, 43,44 signs.
In view of the cerebellar involvement, HDL4/SCA17 was considered likely and 
mutation analysis of the TBP gene eventually revealed a pathological expansion 
of 46 CAG/CAA repeats A diagnosis of SCA17 was made.
With  hindsight,  some  features  in  our patient  were  atypical  for HD  including  a 
myoclonic  component  of  movements  (although  cortical  myoclonus  has  been 
observed in HD). Second, her gait had an additional ataxic component. However, 
the  gait  disturbance  in  HD  is  usually  classified  as  a  frontal  gait  disorder  with 
mixed  hypokinetic-rigid  and  ataxic  features,  in  which  the  postural  imbalance, 
chorea and motor recklessness contribute to frequent falls.  Thus,  the gait in our 
patient was not incompatible with HD. Third, and most importantly, she showed 
mild  upper  limb  ataxia,  and  cerebellar  atrophy  was  present  on  neuroimaging. 
Although  cerebellar  involvement  has  been  reported  in  HD,  this  is  very  rare  in
34adult onset cases and usually consists of mild cerebellar ataxia in  early disease 
stages.
SCA17  HDL  presentation  has  to  date  been  observed  only  sporadically  or  in 
solitary individuals within a family. HDL phenotypic homogeneity in SCA17 has 
not been described. Our family is an example of that SCA17 can present with a 
HDL syndrome in multiple family members.
2.  What to consider in a patient with a negative HD gene test? - The
Huntington’s disease like (HDL) disorders
o
Since  identification of the HD gene in  1993  ,  it has been recognized that what 
appears  to  be  HD  phenotypically,  is  genetically  heterogeneous  and  a  small 
proportion  of  patients  with  a  clinical  syndrome  of  HD  do  not  have  the  HD- 
causing trinucleotide repeat expansion in the IT15 gene. For example, in a report 
of 618 patients 45,  only 93% of those  with a classical clinical phenotype of HD 
were found to have  the HD mutation,  thus providing evidence for the existence 
of other genetic  disorders  which  are  referred  to as  “Huntington’s  disease-like” 
(HDL) syndromes. A number of unrelated genes have recently been identified.38' 
41  Thus, clinicians have to consider an increasing range of differential diagnoses 
when confronted with a patient with slowly progressive, adult-onset chorea and a 
positive family history.  In  view of this growing list of recognized disorders,  we 
have  reviewed  the  commonest  genetic  causes  of  chorea  with  focus  on  the 
spectrum  of  HD-like  disorders  (Review  in  Nature  Clin  Practice46).  We 
concentrated on the autosomal dominant conditions. However, because about 8% 
of HD patients present without apparent family history, chorea with other modes 
of inheritance should also be considered.
35a)  HDL1
HDL1  is  an  autosomal  dominant  progressive  adult-onset  neurodegenerative 
disorder due to insertions of 192bp-nucleotides and  168bp-nucleotides encoding 
extra  octapeptide  repeats  in  the  region  of  the  Prion  protein  gene  (PRNP)  on 
chromosome  20pl2.38,47,48.  The  clinical  picture  may  be  similar  to  HD  with 
abnormal involuntary movements, difficulty in coordination, dementia, personality 
changes and psychiatric symptoms. 49 Seizures have been also described 38. Mean 
age at onset is 20-45 years. Atrophy of the basal ganglia, the frontal and temporal 
lobes 38 and the cerebellum, with kuru and multicentric plaques labeled with anti­
prion  antibodies  was  demonstrated  on  neuropathological  exam.  47,49  Despite  the 
clinical  suggestion of spongiform encephalopathy,  spongiosis  was not prominent. 
The normal  form of the encoded prion protein (PrP  ) is attached to the cellular 
membranes through a glycophosphatidylinositol anchor and has -  among others- 
a  copper  binding  site.  The  normal  function  of  the  protein,  however,  is  ill 
understood. 50 The conformational conversion and transformation of the cellular 
isoform to the pathogenic protein is believed to play a main role in pathogenesis. 
It has been suggested that the site of this formation and subsequent accumulation 
affecting  different  brain  regions  may  contribute  to  the  broad  phenotype  and 
existence of pathologically distinct prion disease entities.51 Overall this seems to 
be a rare genetic cause of HD phenocopies43,52 53.
b)  HDL2
HDL  2  appears  to  be  responsible  for  about  2%  of  patients  without  the  1T15
mutation.  43,45  The  frequency  is,  however,  higher in  black  South  Africans  where
HDL2 contributes significantly to the HD phenotype. 54 56 To assess this further,
Krause et al.56 genetically tested 149 South African patients with a HD phenotype.
36Whilst 84% (78/93) of white patients had the IT15 expansion, only 36% (18/50) 
of black patients and 50%  (3/6)  of mixed-ancestry patients  were  found to have 
the HD-causing mutation. However, 24% (12/50) of black patients and 50% (3/6) 
of mixed-ancestry patients had HDL2-causing expansions. It has been suggested 
that the disorder is due to a founder effect originating in Africa between 300 and 
2000  years  ago.  56  North  American  and  Mexican  HDL2  families  with  African 
origins  have  been  described.  57  With  the  exception  of  one  Brazilian  family  of
CO
Spanish/Portuguese  ancestry  *   ,  HDL2  has  not  been  reported  in  Caucasian  or 
Japanese.52-53- 55- 57
Onset is in the third-fourth decades with a clinical picture resembling classic adult- 
onset HD.  Similarities  with  the juvenile-onset variant have  also been described 
(pedigree  W),  however,  with  the  absence  of  seizures  and  often  normal  eye 
movements.39
Pathological  examination  showed  a  picture  indistinguishable  from  classic  HD 
54,59  j j ie   digoj-jjgj-  i s  caused by a CTG/CAG expansion on chromosome  16q24.3 
in  the Junctophilin-3  gene  60  with  an  inverse  correlation  between  age  of onset 
and repeat  length.  The  function  of junctophilin  remains  unknown  but  a  role  in 
junctional  membrane  structures  and  in  the  regulation  of  calcium  has  been 
suggested.  61.  In  the  normal  population,  the  repeat  length  ranges  from  6  to  27 
CTG/CAG  triplets  61.  Pathological  repeat  expansions  range  from  43  to  57 
triplets, with length instability in maternal transmission.54. To date, the impact of 
alleles  with  from  36  to 39  triplet repeats  is  uncertain.  54  Pathogenicity  may  be 
related to the presence of mRNA inclusions 6~.
In about  10% of cases with HDL2, acanthocytes can be detected in the peripheral 
blood smear. 61,63
37c)  HDL3
Al-Tahan et al. 64 and Kambouris et al. 40 reported an autosomal recessive variant of 
HD from Saudi Arabia presenting with early-onset mental deterioration, dysarthria, 
dystonia,  pyramidal  signs,  ataxia,  and gait  impairment.  Onset age  was  3-4 years. 
Progressive  atrophy  of  the  caudates  bilaterally  and  the  frontal  cortex  was 
demonstrated  by  brain  imaging.  The  condition,  named  HDL3,  was  mapped  to 
chromosome 4pl5.3 40, however, weakness of the evidence has been suggested 65. 
Although  this condition  has  been  named  HDL3,  it does  not fit into the  group  of 
HDL syndromes with respect the age of onset and the pattern of inheritance.
d)  HDL4 / Spinocerebellar ataxia 17
HDL4  has  now  been  identified  as  spinocerebellar  ataxia  (SCA)  17  and  is  an
autosomal  dominant  triplet  repeat  disorder  due  to  mutation  of  the  TBP  gene,
encoding  for  the  TATA  box-binding  protein  (TBP),  an  important  general
transcription initiation factor, on chromosome 6q27.66 Normal CAA/CAG repeat
stretches  range  from  25  to  42  in  Caucasians,  with  larger  repeats  considered
pathological.  Reduced penetrance has been reported for alleles with 43-48 CAG
repeats.67  Onset  age  is  between  19  and  48  years  with  rare  childhood  onset.68
Similar to HD,  there  is an  inverse correlation  between the age of onset and the
number  of  repeats.  Although  cerebellar  ataxia  is  the  most  common  feature
(94%),  the  phenotype  is  markedly  heterogeneous,  and  extrapyramidal  (73%),
pyramidal  (37%),  epilepsy  (22%),  dementia  (76%),  or psychiatric  disturbances
(27%)  may  be  prominent.  69  A  clinical  picture  indistinguishable  from  classical
HD  has  been  reported  in  both  heterozygous  and  homozygous  mutation
carriers.41’70 Although  within most families an HD-like presentation  is observed
only  sporadically,  a homogeneous  HDL phenotype  in  all  members  of a SCA17
3837 family has recently been described by us (see section Chapter 3 1.1).'  The broad 
spectrum of clinical manifestations correlates with the neuropathological findings 
of cerebellar  pathology,  involvement  of the  cerebral  neocortex,  basal  ganglia, 
and hippocampus.71  Intranuclear neuronal inclusion bodies with immunoreactivity 
to anti-TBP and anti-polyglutamine widely distributed in the grey matter have been 
described.7 1
Cerebellar and cortical atrophy are demonstrated on brain MRI. 37 Neuroimaging 
studies  using  DAT-  and  IBZM-SPECT,  and  PET  revealed  reduced  activity  of 
dopamine  transporters,  reduced  glucose  metabolism  in  the  striatum  and  mildly 
reduced  dopamine  D2  receptor-binding  capacity.  72.  In  patients  with  the  more 
common ataxic phenotype voxel-based morphometry showed degeneration of the 
grey matter in the cerebellum, occipito-parietal cortical areas and the basal ganglia, 
reflecting and associated with the cerebellar, pyramidal and extrapyramidal signs. 
Similarly, ataxic patients have been studied electrophysiologically.74 EMG, nerve 
conduction  studies,  visual  and  brainstem  auditory  evoked  potentials,  and 
transcranial  magnetic  stimulation-induced  motor  evoked  potentials  appeared 
normal in all. However, somatosensory evoked potential abnormalities consisting 
mainly of PI4 and P31  wave absence and a prolonged central motor conduction 
time were noted.
e)  A summary of HDL disorders
To  sift  through  the  HDL  disorders,  one  must  pay  attention  to  certain  clinical
features.  Prominent  myoclonus  may  indicate  HDL1  or  DRPLA.  On  the  other
hand,  if cerebellar  signs  are  marked,  or  cerebellar  atrophy  is  demonstrated  on
neuroimaging,  the  SCAs  and  DRPLA  come  into  consideration.  In  the  latter
condition,  high-intensity  signals  of the  cerebral  white  matter,  the  basal  ganglia
39and brain stem on T2-weighted MRI, in addition to atrophy of the brainstem and 
cerebellum,  may  be  present.  However,  this  is  predominantly  observed  in  late- 
onset  adult  DRPLA  patients  with  a  long  disease  duration  and  only  rarely 
observed  in  juvenile  patients  with  a  short  disease  history.  PKAN  and 
neuroferritinopathy have characteristic  MRI imaging,  and additionally chorea is 
rarely an  isolated movement disorder in  these conditions in  which dystonia and 
other  features  may  be  dominant.  Prominent  orolingual  involvements  with 
dystonic tongue protrusion are characteristic of PKAN and chorea-acanthocytosis 
75 and these disorders also differ from classic HD in their pattern of inheritance.
Treatment  for the  conditions remains  symptomatic.  Tetrabenazine  or dopamine 
receptor-blocking agents can alleviate the chorea. More disabling for the patient 
however, often are the psychiatric features and mood disturbances, in which case 
antidepressants may be indicated. Genetic counselling is facilitated by making a 
molecular  diagnosis,  which  is  increasingly  possible,  although  may  still  be 
challenging.  Social  services  and  ancillary  agencies  support,  as  well  as 
occupational,  speech and physiotherapy are important components of treatment, 
and should not be neglected.
3.  Huntington’s disease phenocopies are clinically and genetically
heterogeneous
In a further step, we wished to ascertain the prevalence of HDL disorders among 
patients who are negative for HD mutations. We thus screened DNA samples of 
285  patients  with  syndromes  consistent  with  HD,  who  were  HD  expansion- 
negative, for mutations in PRNP, JPH3,  TBP,  DRPLA,  SCAJ, SCA2,  SCA3,  FTL 
and FRDA.
4041Table 3.1 Clinical characteristics of subjects successfully diagnosed by 
genetic analysis in this 285-patient HD phenocopy cohort (from Wild et 
al76)
We76 identified five cases of HDL4, one of HDL1  and one of HDL2. One patient 
had Friedreich’s ataxia. There were no cases of DRPLA, SCA1, SCA2, SCA3 or 
neuroferritinopathy.  A  summary  of  the  clinical  characteristics  of  subjects 
successfully  diagnosed  by  genetic  analysis  in  this  285-patient  HD  phenocopy 
cohort is given in table 3.1.
Our work  led to the conclusion that among patients with a HD like condition a 
definitive genetic diagnosis is currently possible in only a minority of cases.
II.  Clinical delineation of young-onset parkinsonism and related 
disorders
As  mentioned  above  the  onset  of  parkin-related  parkinsonism  may  be  with 
exercise-induced paroxysmal dyskinesias. These are characterized by involuntary 
movements triggered by prolonged exercise.  Symptomatic forms may be due to 
lesions  in  the  basal  ganglia.  Primary  cases  may  be  sporadic  or  inherited. 
Underlying gene mutations have not been identified.
1.  GLUT1 mutations are a cause of paroxysmal exercise-induced
dyskinesias
During  the  PhD  period,  in  international  collaboration,  we  have  been  able  to 
identify  the  underlying  gene  causing  paroxysmal-exercise  induced  dyskineias.
42We  identified  mutations  in  the  GLUT1  gene.30,77  A  cation  leak  resulting  in 
reduced  glucose  transport  into  erythrocytes,  as  demonstrated  by 
electrophysiological and transport assays, may play a pathophysiological role in 
some of the cases who have hemolysis or echinocytosis.
2.  Parkinsonism-Dystonia -  characterization of PLA2G6 as a
causative locus
In  patients  with  recessive  dystonia-parkinsonism,  the  differential  diagnosis  is
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complex.  In addition to the parkinsonism loci PARK2  , PARK6  (chromosome 
lp,  OMIM 608309), PARK779  (chromosome  lp, OMIM 602533) and the dopa- 
responsive dystonias,  but also pantothenate kinase-associated neurodegeneration 
(PKAN, also called Hallervorden Spatz disease or Neurodegeneration with Brain 
iron  Accumulation  (NBIA)  type  1)  caused  by  mutations  in  PANK2  on 
chromosome 20 (OMIM 234200)80, Kufor-Rakeb syndrome caused by mutations 
in  ATP13A2% X   on  chromosome  lp  (OMIM  606693)  and  DYT16  linked  to 
mutations  in  PRKRA  on  chromosome  282  may  present  with  parkinsonism- 
dystonia, some of these syndromes complicated by pyramidal or other features.
In order to find the causes of parkinsonism dystonia in consanguineous families 
and to better group them for clinical characterization and to identify any families 
which  do  not  have  mutations  in  the  known  loci,  we  have  embarked  on  a 
systematic  screening  using  whole  genome  genotyping  methods82  to  identify 
which  families show homozygosity at the  different loci  and then  sequenced the 
family  members  to  find  the  homozygous  gene  mutations.  We  identified 
homozygosity on chromosome  22 and,  subsequently  PLA2G6  mutations in  two
43families. These individuals did not fit the previously described phenotype of this 
syndrome,  which  is  of  Infantile  Neuroaxonal  Dystrophy  (INAD)  which  is 
clinically  characterized  by  mental  retardation,  early  cerebellar  degeneration
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pyramidal signs and visual disturbances.  In contrast, our two unrelated families 
with a yet unrecognized phenotype of PLA2G6 gene mutations that is adult-onset 
complicated parkinsonism without brain accumulation on brain MRI.
Age  of  onset  was  in  early  adulthood,  at  age  26  and  18  in  our  index  cases, 
however  there  was  intrafamilial  heterogeneity  with  one  affected  cousin  being
84 affected from age  10. This onset age was  later than in PLA2G6-related INAD 
which  begins  before  age  2  and  typically  causes  death  around  age  7-10. 
Presenting  signs  in  our  patients  were  cognitive  decline  in  one  and  walking 
difficulty due  to leg dystonia in the other two.  Onset was subacute resulting in 
severe motor and cognitive handicap within few years, when a full blown picture 
of extrapyramidal,  pyramidal  and cognitive/psychiatric  features  had developed. 
Cognitive  features  were  characterized  by  frontal  executive  dysfunction, 
accompanied  by  personality  changes  and  depression.  One  patient  had  bladder 
dysfunction  and  swallowing  difficulties  later  in  the  course.  Parkinsonism  was 
reflected by marked reduction  of uptake on  dopamine  transporter SPECT scan, 
which  differed  from  the  pattern  seen  in  idiopathic  Parkinson’s  disease,  and 
improved with dopaminergic  treatment.  However,  those on  levodopa developed 
prominent and early dyskinesias.
Mutations  in  PLA2G6  also cause  NBIA  and  iron  was  present  in  all  PLA2G6-
o < 5
related NBIA cases recently described.  ~   In addition to marked cerebellar atrophy 
and progressive white matter changes, iron accumulation of the pallida (affecting 
medial  and  lateral  portions)  were  also  detected  in  further  six  PLA2G6-related
44INAD patients.84 In one, iron was not (yet) present on T2-weighted imaging (T2* 
scans not presented)  2  years  after disease  onset but prominent on  both T2  and 
T2*-weighted MRI on 6-year follow up.  Our finding of absent iron in the basal 
ganglia  as  confirmed  by  T2*  weighted  imaging,  up  to  12  years  after  disease 
duration,  illustrates  that  a  diagnosis  of  PLA2G6-related  neurodegeneration 
should not only be considered in patients with dystonia-parksinsonism with brain 
iron accumulation but also those without.
83 VEPs  and EMGs  which  are  typically  abnormal  in  classic  young-onset  INAD 
were normal in our patient.
Pathologically,  INAD  is  characterized  by  axonal  degeneration  with  distended 
axons  (spheroid  bodies).  However,  there  is  evidence  for  pathological 
heterogeneity of INAD as cases with clinical and pathological features of INAD 
negative for PLA2G6 mutations and in contrast PLA2G6-positve patients without 
spheroid bodies have both been described.85 Pathological data regarding brain or 
peripheral nerves for patients with adult-onset PL42G6-related NBIA are not yet 
available.  However,  a  skin  biopsy  was normal  in  our case  without evidence  of 
spheroid bodies.
Clinically, our patients showed striking resemblance to Kufor-Rakeb syndrome86 
where disease onset was at age  12-15  years,  within the age range of our cases. 
However,  none  of the  additional  clinical  features  of facial-faucial-finger  mini­
myoclonus, visual hallucinations, or oculogyric dystonic spasms found in further 
Kufor Rakeb cases87 were present in our cases.  There also was clinical overlap 
with PKAN. However, lack of the “eye of the tiger” sign on MRI, the absence of
75 oromandibular dystonia which is often severe in PKAN patients \  as well as the 
absence of pigmentary retinopathy appears to distinguish the syndromes.88
45Both  mutations  identified  by  us  (p.R741Q  and p.R747W)  are  novel:  however, 
mutations  at codon  741  have  been  reported recently  (p.R741W  in  a  child  with 
INAD89) and the clustering of mutations at this part of the protein suggests this 
domain is critical for its function.  Little, however, is known about this function. 
The  clinical  and  pathological  similarity  of  the  syndrome  caused  by  PLA2G2 
deficiency to those caused by PKAN and ATP13A2 deficiencies suggest that all 
three  gene  products  may  lie  on  a  single  biochemical  pathway.  Other  genes 
involved in remaining similar syndromes may map to this same pathway.
46Chapter 4  Transcranial magnetic Stimulation (TMS)
Transcranial  magnetic  stimulation  (TMS)  is  a  non-invasive  method  of 
stimulating  cortical  neurons.  A  magnetic  field  generator  drives  a  current  of 
approximately 200/ts with a peak amplitude of 8,000 A through an induction coil 
placed  on  the  scalp.  The  current  creates  a  time-varying  magnetic  field 
perpendicular  to  the  coil.  The  magnetic  field  penetrates  the  skull  and  then 
induces an eddy current parallel to the coil in the brain. This current is capable of 
stimulating  the  brain  and  can  produce  descending  volleys  in  the  corticospinal 
pathway  which  can  be  recorded  using  surface  EMG  from  the  appropriate 
muscles.
The  motor “hot  spot”  is  the  area  on  the  scalp over which TMS  of a particular 
intensity  produces  the  largest  motor  evoked  response  (MEP)  from  the  target 
muscle. Due to ease of stimulation, the most commonly used target muscle is the 
first  dorsal  interosseus  (FDI).  Surface  EMG  is  recorded  from  FDI  during 
stimulation, and once the “hot spot” has been identified it is marked on the scalp.
A  figure  of eight  coil  is  often  used to provide  a more  focal  stimulus  than  that 
obtained from a simple circular coil. If a figure of eight coil is held such that the 
TMS pulse causes current to flow in an posterior-anterior direction perpendicular 
to  the  central  sulcus,  then  this  tends  to  provide  the  lowest  threshold  for 
stimulation and appears to activate corticospinal neurons trans-synaptically.90 As 
stimulation  intensity  is  increased,  a  rising  proportion  of  activation  occurs 
directly.
The  tendency  for  trans-synaptic  activation  means  that  the  response  to  TMS  is 
altered by the excitability of these synapses at the time of stimulation. Therefore
47TMS  is  useful  as a technique  to explore  the integrity  and excitability of motor 
pathways,  and  can  be  applied  before  and  after  an  intervention  to  determine 
whether a change in synaptic excitability has occurred.
I.  Single pulse TMS measures
1.  Resting and active motor thresholds.
Resting motor threshold (RMT)  is defined as  the  minimum  intensity  needed to 
evoke an MEP of >50/tV  in  5  out of  10 consecutive trials in a relaxed muscle. 
Active motor threshold (AMT) can be defined as the minimum intensity (in % of 
maximum stimulator output) needed to evoke a MEP of >200p,V  in 5 out of 10 
trials in the target muscle while it is voluntarily contracted. Typically feedback is 
given  to  the  subject to maintain  this  voluntary contraction  at a  set  level  (about 
20-30%  of maximal contraction).  Thresholds are a marker of excitability.  They 
both  mainly  reflect axonal  excitability;  however synaptic  excitability  may  also 
play a role in RMT production.
Spinal  excitability  also contributes  to MEP size.  To  assess  whether changes  in 
MEP size are due to cortical or spinal changes, assessment of H-reflexes can be 
useful.91  Assessment of other cortical measures like short afferent inhibition (see 
below) may also be helpful for this distinction.
2.  Input/Output curves
Differences  have  been  observed  in  the  input/output  relationship  in  response  to 
TMS.  In  these  experiments,  the  RMT for a particular individual  is established, 
and then TMS pulses at increasing intensity of stimulation based on percentages
48of RMT are delivered, and the size of the resulting MEP recorded. This provides 
an  input/output  curve  where  MEP  size  is  plotted  against  magnitude  of  TMS 
intensity.
A difficulty with interpretation is that muscle activity directly influences the size 
of  MEP  produced  from  TMS  of  a  given  intensity  of  stimulation.  Muscle 
activation  in  the  target  muscle  or  other  adjacent  or  distant  muscles  (or  even 
thinking  about  muscle  activation)  increases  MEP  size.  This  means  that 
scrupulous monitoring of baseline EMG in the target muscle is required in order 
to prevent this possible artefact in experiments in hyperkinetic subjects, who may 
have  a  significant  amount  of  involuntary  muscle  activity  (such  as  dystonia  or 
rigidity  or  tremor  in  parkinsonian  patients  or  chorea).  This  unwanted 
preactivation may then result in false results of measures “at rest” and it may be 
advisable to study TMS measures during voluntary contraction instead which can 
be  objectively  measured.  It  may also be  useful  in  future  studies  to give  details 
about  clinical  findings  in  the  studied  limbs  (for example  whether  rigidity  was 
present  rather  than  simply  giving  a  total  clinical  score  where  it  is  not  known 
which clinical finding predominated).
3.  Silent Period
The silent period is a period of EMG silence that occurs following a TMS shock
delivered  over  the  representative  area  of  cortex  of  a  voluntarily  contracting
muscle.  To  achieved  a  constant  sub-maximal  muscle  contraction  auditory  or
visual  feedback is usually given.  A TMS pulse is then delivered over the motor
hotspot  at  a  certain  intensity  of  e.g.  110-130%  of  RMT.  A  higher  stimulus
intensity  possibly  provides  a  more  consistent  result.92  The  temporary  break  in
EMG  activity  is  called  the  silent  period.  This  can  be  measured  in  a  variety  of
49ways,  for example by measuring the interval  between the onset of the  stimulus 
artefact and the first recovery of EMG activity. Orth and Rothwell proposed that 
the  ratio  of  the  silent  period  and  MEP  amplitudes  may  be  superior  as  it  is 
independent from parameters like coil orientation and stimulation intensity.92
Studies  in  normal  subjects  typically  find  the  silent  period  to  be  100-120ms  in 
length.  Via  examining  the  effect  of  GABAa  and  GABAb  antagonists  and 
agonists, It was proposed that the SP is a GABAb mediated process.93,94 There is 
likely to be a small additional spinal component.95
4.  Central Motor Conduction Time
The conduction time from the cortex to the spinal alpha motomeuron is referred 
to as central  motor conduction  time.  To establish  CMCT,  the peripheral  motor 
conduction  time  (spine  to muscle)  is  being deducted from the cortico-muscular 
latency. For the latter measure, different methods have been described including 
transcutanous magnetic timulation of the spinal nerve roots.96 In healthy subjects 
increasing stimulation  intensity  leads  to a decrease in CMCT.  Conduction  may 
be  slowed  by  demyelination,  degenerative  or  ischemic  changes  of  the  fastest- 
conducting fibres, or decreased dispersion of the multiple corticospinal discharge 
which results in less temporal summation at the spinal alphaneuron.
II.  Paired pulse TMS measures
1.  Short Intracortical inhibition and facilitation
Kujirai  et  al  97  developed  a  paired  pulse  TMS  technique  which  is  thought  to 
stimulate  different  populations  of  inhibitory  and  excitatory  intemeurons,  and
50provides  measures  of their excitability:  intracortical  inhibition  and  facilitation. 
The  standard  method  explores  the  influence  of a  sub-threshold  “conditioning” 
pulse  on  the  size  of  the  MEP  produced  by  a  subsequent  “test”  pulse.  The 
intensity of the test pulse is usually set to achieve an MEP of about  lmV when 
given  alone.  The  conditioning  pulse  is  then  given  at  different  time  intervals 
(interstimulus intervals, ISIs) prior to the test pulse.
In studies with normal  subjects, the conditioning pulse given  l-5ms prior to the
97 test pulse causes a reduction in the resulting MEP.  This effect is known as short 
interval  intracortical  inhibition  (SICI).  The  effect  is  enhanced  by  GABAa 
agonists,  NMDA  receptor  blockers  and  dopamine  agonists  and  is  blocked  by 
dopamine  antagonists.98,99  It  is  proposed  that  SICI  is  a  GABAa  mediated 
pathway that has an inhibitory influence of corticospinal tract excitability.
There  is a cross-over or intermediate period of response  when  the conditioning 
pulse is given between 6 and 9ms prior to the test pulse, where little effect is seen 
on the resulting MEP. At interstimulus intervals (ISIs) of 10-20ms an increase in 
the  size  of MEP  is  typically  seen,  a  phenomenon  known  as  short  intracortical 
facilitation (ICF).97 It can be modified by rTMS independently of SICI indicating 
that different pathways underlie the two phenomena.100 The mechanism of ICF is 
unclear at the present time.  Currently it is thought most likely to be a glutamate 
mediated event. 98
a)  SICI recruitment curve
SICI  can  be  influenced by  the  intensity  of the conditioning pulse.  Thus,  rather 
than testing effects of different ISIs, effects of varying stimulation intensities of 
the  conditioning  pulse  at  a  fixed  ISI  are  assessed.  SICI  is  recordable  using  a
51conditioning pulse intensity of 60% RMT at an ISI of 3ms. The magnitude of the 
effect  increases  as  the  intensity  of  the  conditioning  pulse  is  increased,  and 
reaches a maximum at approximately 90% of RMT or 80% AMT. 97,101  Further 
increases  in  intensity  lead  to  progressively  less  SICI.  Although  less  certain,  it 
may be that the optimum intensity for producing ICF is slightly higher than that 
for SICI.
2.  Short afferent inhibition
A sensory (afferent) conditioning stimulus,  such as median nerve stimulation or 
digital nerve stimulation, delivered to the contralateral hand can inhibit the motor 
cortex as measureable by decreased motor evoked potential amplitude. Inhibiton 
that occurs at ISIs of 20 ms between the conditioning sensory stimulation and the 
test TMS is referred to as short latency afferent inhibition (SAI).102 103 Inhibition 
occuring  at  longer  ISIs  of  ~200 ms  is  referred  to  as  long  latency  afferent 
inhibition (LAI). 104
III.  Plasticity of the nervous system
The nervous system is able to adapt to (internal or external) stimuli and to remain 
in that changed state until further stimuli occur. In other words: it is plastic. The 
ability  of the nervous  system  to plasticity can  be demonstrated experimentally, 
for  example  using  TMS  methods.  Plasticity  of  the  motor  system  presents  as 
change  in  motor  “maps”  in  the  primary  motor  cortex  (Ml)  in  response  to 
pathological  or physiological  interventions.105  Practicing  and  learning of motor 
skills  induces  plastic  changes  and  expansion  of cortical  representation  of  the 
body  parts  involved  in  the  motor  task  in  primates  and  humans.105  Appropriate
52TMS-challenge can  also result in  such  a change  of the  functional  organisation 
which outlast the period of conditioning (the TMS pulse). This is the case even if 
the pulses are delivered at sub-threshold intensities (i.e intensities of stimulation 
that produce no recordable muscle activation). It is thought that these changes are 
a  form  of  long  term  potentiation  (LTP)  and  long  term  depression  (LTD)  (see 
under mechanisms).
1.  Repetitive transcranial magnetic stimulation
Various  protocols  of rTMS  have  been  devised  for  the  induction  of  long-term 
changes  in  cortical  excitability.  However,  it  was  found  that  high  frequency 
stimulation  (20Hz  and  above)  comes  with  the  risk  of  inducing  seizures  in 
humans.106  Subsequently, international safety guidelines were introduced which 
restrict the frequency of stimulation that may be applied to human subjects.107
Low-frequency rTMS, most commonly used at a frequency of 1   Hz, delivered at 
90%  resting  motor  threshold  applied  for  20-30  minutes  produces  an  LTD-like 
effect  which  can  be  measured  for  about  30-40  minutes  from  the  end  of 
conditioning.108110  Electrophysiologically,  this  LTP  effect  can  be  measured  as 
decrement in the amplitude of motor evoked potentials as compared to MEP size 
prior to rTMS application.
In  contrast,  high-frequency rTMS,  e.g.  5Hz  rTMS,  induces  LTP-like  effects  in 
human  cortex.  To  avoid  coil  overheating  or  other  technical  problems,  such 
stimulation is given in blocks rather than one continous long train.111,112
There  have  also  been  studies  exploring  the  effect  of yet  higher  frequencies  at 
higher  intensities,  including  20  pulse  trains  at  20  Hz  and  150%  RMT.113
53Similarly  to  5Hz  rTMS,  these  protocols  produces  short  lasting  (seconds  to 
minutes) increments in cortical excitability.
2.  Theta-burst TMS
Recently,  Huang  et  al114  developed  a  protocol  of  rTMS,  called  theta  burst 
stimulation (TBS),  which produces longer lasting effects of 60 min following a 
brief stimulation period of 90-120 sec.  Patterns of TBS  include  the  intermittent 
theta  burst  stimulation  pattern  (iTBS)  and  continuous  theta  burst  stimulation 
paradigm  (cTBS).  Pulses of stimulation are given at 50 Hz, repeated every 200 
ms. In the intermittent theta burst stimulation pattern (iTBS), a 2 s train of TBS is 
repeated every  10 s for a total of 190 s (600 pulses). In the continuous theta burst 
stimulation  paradigm  (cTBS),  a 40  s  train  of uninterrupted TBS  is  given  (600 
pulses).
The direction of change in synaptic efficiency (facilitatation following iTBS  vs 
inhibition following cTBS) depends on the pattern of TBS delivery. Facillitation 
is seen following iTBS (similar to high frequency rTMS), while continuous TBS 
has inhibitory effects (similar to low-frequency rTMS).
Figure 4.1 Graphical illustration of TBS paradigms (A) and their effects on
MEPs (B). (from Huang et al114)
543.  Interventional Paired associative Stimulation (IPAS)
Plastic  changes  in  the  excitability  of  motor  cortical  pathways  in  humans  that 
outlast the period of stimulation by minutes to hours can also be produced using 
paired  pulse  stimulation  protocols.115  Here,  a  sensory  afferent  (via  direct 
stimulation of a nerve) and the homologous cortical efferent (via a single TMS 
pulse over the corresponding area of motor cortex) pulse are given together.
Dependent  on  the  timing  of  the  pulses,  increases  or  decreases  in  cortical 
excitability can be produced (similarly to SICI and ICF). For example, if median 
nerve  stimulation  is  given  25  ms  before  TMS,  low-frequency  median  nerve 
stimulation, paired with suprathreshold transcranial magnetic stimulation (TMS) 
over the optimal site for activation of the abductor pollicis brevis (APB) muscle 
typically induces a long-lasting increase in the excitability of corticospinal output 
neurons.
On  the  other  hand  a  gap  of  10ms  between  sensory  stimulation  and  cortical 
stimulation causes a decrease in cortical excitability.116
In  humans,  the  effects  of IPAS  can  be blocked by NMDA  antagonists  such  as 
dextromethorphan.
4.  Behavioural effects of TMS- or DCS-induced plasticity
In  addition  to  changes  in  electrophysiological  measures,  e.g.  MEP  size, 
plasticity-inducing TMS or DCS protocols can result in alterations in behaviour. 
For example, serial reaction time tasks may be affected by rTMS. In recent years 
effects of rTMS on behaviour has been studied not only in healthy volunteers but 
also in patients with varies neurological and psychiatric diseases with the aim of
55improving symptoms.  117 (see below for effects of rTMS application in selected 
movement disorders)
5.  Mechanisms of plasticity
The  mechanisms  of plasticity are  not fully  understood.  Brain  slice experiments 
allow measuring field potentials (FP) and the response to stimuli. Changes in the 
FP  in  response  to  conditioning  pulses  provide  a  direct  measure  of changes  in 
synaptic strength. This approach allows manipulation of conditioning stimuli and 
physiological  conditions  in  order  to  better  understand  the  mechanisms  of 
synaptic plasticity. Both pre- and postsynaptic mechanisms have been described.
Changes  at  the  pre-synaptic  level  are  related  to changes  in  the  amount  and/or
1  1  8
probability of transmitter release (for example calcium influx),  availability of 
vesicles,  growth of the bouton, or number of boutons and result in short lasting 
changes  in  synaptic  efficiency  (lasting  milliseconds  to  seconds).  At  the  post­
synaptic  level,  plasticity  occurs  via  glutamate  receptors.  While  high  frequency 
direct  electrical  stimulation  causes  long-term  potentiation  (LTP)  as  shown  in 
animal brain slice preparations119, low-frequency stimulation produces long-term 
depression.120
LTP,  in  general,  is  an  NMDA  receptor-dependent  process,  so  that 
pharmacological121,122 or genetic123 blockade of these receptors leads to reduction 
of after-effects of plasticity protocols with failure of LTP induction.
56Chapter 5  TMS in Genetic Movement Disorders
TMS  has  been  used  to  explore  various  neurological  and  psychiatric  disorders, 
however,  in many of the studies the cohorts were etiologically and/or clinically 
hetereogenous  (for  example,  Parkinson’s  disease  is  probably  a  heterogenous 
disorder  with  different  subtypes).  Consequently,  results  have  varied  and  have 
sometimes been inconclusive.
With identifaction of genes underlying diseases there has been increasing interest 
in  using TMS  for assessment of genetic  conditions  as patients can be recruited 
based  on  their  molecular  diagnosis  to  ensure  a  homozygous  study  cohort.  A 
relatively  small  number of studies based on  such concept have been  published 
including  some  focusing  on  non-movement  disorder  patients124'128  In  the 
following the current knowledge of TMS in genetic movement disorders will be 
reviewed. A summary is given in the Appendix (table 5.1)
I.  TMS in Genetic Parkinson’s disease
There has been extensive research into Parkinson’s disease using TMS; however, 
except for two studies, patients had the idiopathic form. Only very recently, two 
studies assessed parkin-related parkinsonism, one study focussed on patients, the 
other  one  reported  data  obtained  from  carriers.  To  date  no  other  monogenetic 
forms of Parkinson’s  disease  (PINK1,  DJ1,  LRRK2)  have  been explored using 
TMS.
1  ^9 In  idiopathic  PD  (see  Cantello “  et  al  for  review),  the  main  findings  include 
shortening  of CSP,  reduction  in  SICI,  but  normal  thresholds,  normal  ICF  and 
normal CMCTs. Levodopa was found to restore the abnormal measures.
57In the study on parkin disease with four patients, De Rosa et al130 found evidence of 
prolonged CMCT. In detail, CMCT was slow in two patients in both upper and lower 
limbs.  A  further  patient  had  abnormal  CMCT  in  the  arm  and  the  fourth  patient 
abnormal  CMCT in the leg.  Further findings were increased MEP thresholds  in  two 
patients  and  decreased  thresholds  in  one  patient.  Two  patients  had  shortened  CSP. 
However,  other aspects of cortical excitability,  in particular integrity of intracortical 
inhibitory  systems,  have not been  studied,  and it is  unclear  whether parkin  patients 
differ from idiopathic PD patients.
Electrophysiological  studies  of carriers are also limited to one  study.  Recently, 
Baumer and colleagues1 31 reported abnormal short afferent inhibition, a measure 
of  sensorimotor  integration  and  cholinergic  activity,  whereas  short  interval 
intracortical inhibition, mediated mainly by GABAa intemeurons, was normal,132 
Whether this reflected a form of “compensation” or a direct consequence of the 
underlying dopaminergic deficit was unclear.
II.  TMS in Genetic Chorea
Numerous  studies  have  investigated  familial  choreas  using  TMS;  however  to
date  reports  are  only  available  for HD,  and  not  for  the  other forms  of genetic
chorea some of which have been outlined above. Notably, most of these studies
date from the time prior to identification of the HD gene and diagnosis was made
based  on  clinical  features.  Thus,  the  studied cohorts  may  have  been  gnetically
heterogenous.  Only recent studies enrolled patients  with  molecularly confirmed
diagnoses.  This  issue  will  be  considered  in  the  following.  Furthermore,  except 
| ^
for one study ", data did not reflect electrophysiological changes over time.
581.  Single Pulse TMS in HD
a)  Thresholds and Input/Output Curves in genetically proven 
HD
Resting  motor  thresholds  were  normal  in  two  studies  with  17  and  11  patients 
with genetically proven HD.134,135 AMT was also assessed in one of these studies 
and found normal. 134
Similar  results  had  been  suggested  by  previous  historical  reports  based  on  a 
clinical  diagnosis136’137,  however,  Meyer  et  al138  had  found  abnormally  high 
thresholds  and  reduced  MEP  amplitudes  in  up  to  72%  of  34  patients  with 
manifest  HD  and  abnormalitites  correlated  with  duration  of motor  symptoms. 
However, it needs to be kept in mind that these studies were undertaken prior to 
identifaction of the gene.
b)  Silent period in in genetically proven HD
While  selected  trials revealed normal  silent period duration  in  17  patients  with 
genetically  proven  HD,  other  trials  contained  significantly  prolonged  silent 
period durations with a larger variance and range compared to controls.135’139,140 
Lefaucheur et al reported deterioration of silent period measures over time after 
studying 20 patients with gene-proven HD. Mean age of his cohort was 42 years, 
mean CAG repeat 45,3 (range 41-51) and mean duration of evolution 6±2 years. 
He calculated an annual slope of -27±10ms for silent period duration.
The  prolonged  SP  in  HD  opposes  findings  in  PD  where  SP  is  generally 
shortened.
59c)  CMCT in HD
Central motor conduction time was found normal in 32 patients with clinically-
117 diagnosed  Huntington's  disease  and  14  subjects  at  risk.  CMCT  was  also 
normal in patients with early gene-proven HD.1 4 1
2.  Paired pulse TMS masures in HD
a)  SICI/ICF in in genetically proven HD
Abbruzzese et al142 reported reduced cortico-cortical inhibition at intervals of 2-5 
ms  and reduced  ICF at intervals  of  10-25  ms  in  nine  patients  with  genetically 
proven HD with a mean disease duration of 6.2 (±4.1) years.  Analysis revealed 
an  inverse  correlatation  of inhibition  with  onset  age  and  a  positive  significant 
correlation with dyskinesia ratings but not with UHDRS scores.
Two  genetically  proven  pre-symptomatic  carriers  of who,  however,  no  further 
details  like CAG repeat length or predicted years  to onset are known  showed a 
“time course of conditioned MEP changes at paired cortical  stimulation  similar 
to that of normal controls”.142
In a recent study, Nardone et al assessed twelve patients (mean age 33.5  years) 
with  a  molecular  diagnosis  of  HD.  Patients  were in  early  disease  stages,
classified as stage I according to Shoulson and Fahn143.  UHDRS  scores  ranged
from 0 (n=4)  to  13.  The authors  found reduction  in  ICF,  while  other measures 
were normal. 1 4 1
60b) Short afferent inhibition
Short afferent inhibition has not been studied in HD.
3. Plasticity TMS measures in genetic chorea
a) rTMS
Lorenzano  et  al  134  applied  5Hz  rTMS  at  a  suprathreshold  intensity  of  120% 
resting threshold over the Ml  area in eleven patients with a molecular diagnosis 
of HD.  Mean  age  of patients  was  56±10.2  years  (range  40-69),  mean  disease 
duration  was  6±2  years  (range  3-10).  HD  manifested  with  typical  chorea. 
UHDRS  scores  ranged from  11-55  (mean  26±15).  However,  rTMS  resulted  in 
progressive increment of MEP size in controls, however, no changes were seen 
in HD patients. In both groups, cortical silent periods invariably lengthened. 134
Recently,  Crupi  et  al144  probed  LTP-like  plasticity  motor  cortex  in  eight 
genetically proven  (mean UHDRS  31). Two paradigms  were performed.  Motor 
cortex  plasticity  was  assessed  using paired associative  stimulation  (PAS)  at  an 
ISI of 25 ms. Secondly, brainstem plasticity was studied using pairing of an high- 
frequency  train  of  electrical  stimuli  over  the  right  supraorbital  nerve  (SO) 
coinciding  with  the  R2  response  elicited  by  a  preceding  SO  stimulus.145  The 
authors  found impairment of both cortical  and brainstem LTP-like plasticity  in 
their symptomatic HD patients.
614.  Other electrophysiological measures in HD
a)  Blink reflex in HD
R1  components reflect oligosynaptic pons pathways. R1 responses are normal in 
patients with a clinical diagnosis of HD. 146  147
The  R2 component of the blink reflex which is mediated by polysynaptic  brain 
stem pathways has been found abnormal in  11 patients with clinically diagnosed 
Huntington's  chorea  who  showed  prolonged  latencies  ipsilaterally  and 
contralaterally.146
Studies  also  revealed changes  in  amplitude  and  duration  of R2;  however  with 
somewhat  inconclusive  results  with  either  increased  or  decreased  measures 
compared  to  healthy  subjects.146  148  This  may  reflect  high  variability  of R2 
responses in HD.
Finally,  patients  also  showed greater habituation  of R2 responses.  148 150 These 
abnormalities  correlated  with  severity  of  facial  chorea.  146  This  indicates 
depression of the blink reflex in HD due to reduced excitability of polysynaptic 
networks within the brain stem.
b)  Masseter reflex in HD
Cruccu  et  al1 5 1   found  normal  masseter  inhibitory  reflex  latencies,  depth  of 
suppression,  duration  and  recovery  cycle  to  paired  stimuli,  in  patients  with 
clinically diagnosed Huntington's chorea.
c)  H reflex in HD
Priori et al152 reported increased facilitation of the test H reflex recovery cycle in 
the  flexor  carpi  radialis  at  conditioning  test  intervals  of  10-200ms  in  16
62genetically proven HD patients (with a mean clinical severity score of 10.4±1.7 
on the Marsden& Quinn Chorea Evaluation scale (max score 24)). Abnormalities 
were  most  prominent  at  40-60ms.  The  authors  compared  those  to  cortical 
inhibitory  measures  to  determine  the  origin  of the  abnormal  inhibition  patters, 
however, cortical inhibition was found normal (see above).
d)  Reciprocal inhibition in HD
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Priori  et  al ‘  also  studied  reciprocal  inhibition  in  his  patients  with  clinically- 
diagnosed  HD  patients  and  found  a  significantly  decreased  presynaptic  phase. 
This reached a minimum at the conditioning test interval of 20ms.
e)  Bereitschaftspotentials in HD
Absence of pre-movement Bereitschaftspotentials preceeding choreic movements 
led Shibasaki  et al153  to the conclusion  that choreic  movements  of HD patients 
were  indeed  involuntary.  Again,  this  study  was  done  based  on  a  clinical 
diagnosis of HD.
5.  Summary of TMS in genetic Chorea
In  summary, TMS  studies  suggest reduced cortical  excitability in HD based on
the  findings  of  reduced  amplitudes  in  cortical  components  of  SEPs154,  long-
latency  reflexes,155156  premotor  potentials,157  -   in  the  absence  of changes  in
subcortical levels.  134  Deterioration over time affected blink reflex latency, long-
1 latency  reflexes,  SEP  parameters  (N20  and  N30  presence).  '  There  may  be 
variability  of  silent  period  duration  and  abnormalities  in  SICI  suggesting 
alterations  of GABA-ergic  mechanisms.  Progression  of abnormalities  of silent
63period  duration  over  time  was  suggested.133  Plasticity  was  reduced  in  HD
patients.
III.  TMS in Genetic Dystonia
1.  Clinical Overview
Dystonia is defined as “a syndrome of sustained muscle contraction,  frequently 
causing twisting and repetitive movements or abnormal postures” as produced by
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the Scientific Advisory Board of the Dystonia Medical Research Foundation. 
Dystonic  syndromes  can  be  classified  according  to  aetiological  cause  with  the 
main separation being “primary” versus “secondary/heredodegenerative”.158 The 
aetiological  classification  furthermore  includes  paroxysmal  dystonias  and  the 
“dystonia  plus”  syndromes,  dopa-responsive  dystonia  (DRD)  and  myoclonic 
dystonia. These “dystonia plus syndromes” are conditions where dystonia occurs 
together  with  other  movement  disorders,  but  where  there  is  no  secondary  or 
neurodegenerative cause.159
Familial  forms  of dystonia  have  been  recognised  for  many  years,  and  genetic 
investigation  of such  families  have  revealed  a  number  of possible  loci  and  in 
some  cases  particular  gene  mutations.  These  are  largely  summarised  in  the 
“DYT” gene classification system, which currently extends from DYT1 to 16.160
a)  DYT1 Dystonia
As  for  the  “pure”  dystonias,  DYT,  due  to  a  single  GAG  deletion  in  torsin  A 
(TORIA  gene)  on  chromosome  9q34,16 1   classically presents  with young-onset 
lower  limb  dystonia  which  later  spreads  to  become  generalized.  The  cranio-
64cervical  is  usually  spared.  Inheritance  is  autosomal  dominant.  An  increased 
prevalence in the Ashkenazi Jewish population has been noted thought to be due 
to a “founder effect”.
DYT1  dystonia is particularly interesting in the context of the proposed projects 
as penetrance is reduced and clinical  symptoms  in  DYT1  mutation carriers  are 
present  only  in  approximately  30%,  and  almost  all  those  who  are  going  to 
manifest  symptoms  will  do  so  before  the  age  of 25.  DYT1  mutation  carriers 
therefore  present a  unique  opportunity  to  the researcher with  an  interest  in  the 
pathophysiology  of  dystonia  and  consequently  these  subjects  have  been 
particular  given  attention.  Functional  imaging  studies  in  DYT1  have  provided 
clues  that  clinically  normal  individuals  who  carry  the  DYT1  mutation  have 
abnormalities  in  brain  structure  and  function.  TMS  data  in  unaffected  DYT1 
carriers are summarized below.
b)  Dopa-responsive Dystonia (DRD)
A  rare  form  of dystonia  is  DRD  (Segawa  syndrome).  These  patients  typically 
have young-onset limb dystonia and in many cases additional parkinsonism and 
mild  pyramidal  signs.  Diurnal  fluctuations  of  symptoms  is  reported  in  a 
proportion  of  patients  with  worsening  of  symptoms  throughout  the  day.162 
Phenotypic  variability  is  common,  but  in  almost  all  cases  a  dramatic  and 
sustained response to levodopa is seen. For the classic form mutations in the gene 
encoding  guanidine  triphosphate  cyclohydrolase  1   (GTPCH1)  could  be 
identified,  GTPCH1  is  a  rate  limiting  step  in  the  metabolism  of 
tetrahydrobiopterin,  itself an  essential  co-factor  in  the  production  of dopamine 
from tyrosine 163,  164 Mutations in TH4 cause a more severe phenotype.
65Two studies have investigated DRD using TMS.
c)  Myoclonic Dystonia (DYT11)
In  myoclonic  dystonia,  familial  early  childhood  onset  dystonia  (typically 
affecting  the  neck  and  arms)  is  accompanied  by  myoclonus  in  a  similar 
distribution.165  The  myoclonic  jerks  are  described  as  “lightning  jerks”,  and 
alcohol  responsiveness  is  common.165  Recently,  mutations  in  the  epsilon 
sarcoglycan  gene  (SGCE)  have  been  found  in  a  proportion  of  patients  with 
myoclonic  dystonia.166  The  gene  shows  maternal  imprinting,  meaning  that 
offspring  receiving  a  mutant  gene  from  their  mother  will  almost  never  show 
symptoms,  in  contrast  to  those  who  receive  a  mutant  gene  from  their  father, 
where penetrance  is  almost complete.167 To date one TMS  studies focussed on 
myoclonic dystonia patients.
d)  Paroxysmal Dystonia/ Dyskinesias
Furthermore,  genetic  causes  have  been  identified  for  some  of the  paroxysmal 
dyskinesias /dystonias  -  a  condition  where  dystonia  occurs  in  attacks  whereas 
patients  do  not  show  any  signs  interictally.  Based  on  the  classification  by 
Demirkiran  and  Jankovic168  four  formes  can  be  distinguished:  paroxysmal 
kinesigenic  dyskinesias  (PKD),  paroxysmal  non-kinesigenic  dsykinesias 
(PNKD),  paroxysmal  exercise-induced  dsykinesias  (PED)  and  paroxysmal 
hypnogenic  dsykinesias  (PHD)  according  to  triggering  factors  (sudden 
movement  (PKC),  prolonged  exercise  (PED),  emotions/  fatigue  (PNKD)  and 
sleep  (PHD)).  Responsible  genes  have  recently  been  identified  for  PNKD  and 
PED. In the former mutations have been found in the MR1  gene on chromosome 
2.169  In  the  latter,  familial  and  sporadic  cases  were  recently  found  to  carry
66mutations in GLUT1, encoding for a glucose transporter which provides the CNS 
with  glucose  (see  above  under  Clinical  Experiments).  In  PHD  mutations  on 
chromosomes  15q24 and 20q 13.2-13.3 coding for the <a>4 and <b>2 subunits of
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nicotinic acetylcholine receptors (nAChRs) have been identified.
Two  TMS  studies  focussed  on  paroxysmal  dyskinesia,  however diagnosis  was 
made on a clinical basis and not genetically confirmed.
2.  TMS in Dystonia
A  wealth  of  electrophysiological  and  imaging  data  exists  in  patients  with 
dystonic  syndromes  whereas  data for genetic  dystonia are  limited to  studies  in 
DYT1  dystonia, DRD and paroxysmal dyskinesia /dystonia. Three studies report 
data of DYT 1  dystonia, including one assessing effects of deep brain stimulation. 
TMS data of dopa-responsive dystonia and paroxysmal dyskinesias are limited to 
two  studies  each  and  there  is  one  study  on  myoclonic  dystonia.  No  data  are 
available for any of the other DYT-realated forms of dystonia.
a)  Single pulse TMS measures in Dystonia
(i)  Thresholds in Dystonia
Abnormalities  in non-genetic  dystonia patients include a significantly enhanced 
input/output curve,  such  that MEP size  is  significantly  larger for a  given  input 
compared  to  control  subjects  171172  interpreted  as  increased  excitability  of  the 
motor  system,  although  no  differences  have  been  found  in  thresholds  for 
activation  of  muscles  in  sporadic  dystonia  subjects  compared  to  controls. 
Similarly,  thresholds  were  normal  in  genetic  dystonias  including  DYT1
67manifesters and carriers173, DRD174 and paroxysmal dystonia. 175 Increased active 
motor thresholds have been reported in five gene-proven DYT11  gene carriers.176
(ii)  Silent Period in Dystonia
In  dystonic  subjects,  including DYT1  manifesting patients and non-manifesting
177  179 subjects,  a  number  of  studies  have  found  a  shortened  silent  period 
suggesting  deficits  of GABAb  circuits,98  whereas  the  silent  period  was  found
180  175  181 normal in DRD  and paroxysmal dyskinesias.  *’
b)  Paired pulse TMS measures in Dystonia
(i)  SICI and ICF in Dystonia
SICI  appears  to  be  reduced in  patients  with primary  dystonia including DYT1 
cases,177’173’178’182 DRD180 and paroxysmal dyskinesias.1 8 1   SICI was also reduced 
in DYT1  carriers.179 This has been interpreted as a failure of probably GABAa- 
dependent98 inhibitory control of motor pathways which could lead to problems 
in focusing desired movement and could lead to unwanted  muscle activity.177  As
with  input-output  experiments,  measurement of SICI  (and ICF) is  hampered  by
muscle contraction -  it will tend to reduce SICI and ICF.  However, reductions 
in  SICI  have  been  demonstrated  using  target muscles  that are  not involved  by 
dystonia (e.g. FDI in patients with cervical dystonia).
Others  found  normal  SICI  in  other  genetic  dystonias  including  gene-proven 
myoclonus dystonia, DRD and paroxysmal dyskinesias. 174176
ICF is normal in genetic dystonias.179'1 8 1
(ii)  Short Afferent Inhibtion in Dystonia
68Short  afferent  inhibition  (SAI)  is  typically  normal  in  patients  with  (sporadic) 
dystonia.  Long  afferent  inhibition  (LAI)  was  found  abnormal  in  patients  with 
writer’s  cramp,  but not  in  cervical  dystonia,  suggesting  a  different  mechanism 
from LAI. 184’185
SAI was normal in five gene-proven patients with myoclonus dystonia.  SAI has 
not been assessed in other genetic dystonias.
c)  Plasticity in Dystonia
rTMS,  theta  burst  stimulation  and  IPAS  have  been  used  to  study  plasticity  in 
dystonic  syndromes.  With  respect  to  genetic  dystonias,  only  DYT1  has  been 
assessed  173 178186.  Here, rTMS, rTMS paired with DCS187  and PAS have been 
explored.
In  both  non-genetic  and  genetic  dystonia plasticity  is  increased.  Interventional
paired  associative  stimulation  (IPAS)  produced  more  stimulation-induced
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facilitation  of  MEP  amplitudes  in  focal  arm  dystonia  patients  ;  1Hz  rTMS 
prodcued more widespread changes in the cortex of patients as demonstrated by 
PET.189  In  DYT1  patients  1   Hz  rTMS  over  the  premotor  area  produced  a 
significant increase in reciprocal  inhibition  (affecting the third and possibly the
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first  phase),  while  no  changes  were  observed  in  controls.  Theta  burst 
stimulation produced a significantly prolonged response in eight DYT1  patients 
compared  to  healthy  subjects  (see  Figure  5.1).173  Notably,  in  DYT1  carriers
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theta burst stimulation resulted in a reverse (or: lack of) response.
69Figure  5.1  The  normalized  motor  evoked  potential  (MEP)  size  at 
baseline  and  following  repetitive  transcranial  magnetic  stimulation 
(rTMS)  in  healthy  subjects,  manifesting  DYT1  mutation  carriers 
(MDYT1),  subjects with torticollis,  and nonmanifesting DYT1  mutation 
carriers  (NMDYT1).  Error bars  indicate  the  standard error of the mean.
(from: Edwards et al173)
d)  Other Electrophysiological Measures in Dystonia
(i)  Blink Reflex in Dystonia
The  blink  reflex  has  been  found  enhanced  in  certain  types  of  non-genetic
dystonia  (blepharospasm,  cervical  dystonia,  generalised  dystonia)  such  that  the
R2 component is large even at ISIs of 250-500ms.190-193 Similarly, patients with
dopa-responsive dystonia were found to have an abnormal blink reflex recovery
cycle at 200, 500 and  1000ms180 when studied “off’ treatment. The authors also
found that the significant increase in the excitability of the blink reflex recovery
cycle  decreased  with  levodopa  treatment.  Similar  normalization  has  been
70reported  for  idiopathic  PD.194  Blink  reflex  data  for  other  genetic  forms  of 
dystonia including DYT1 and paroxysmal forms are not available.
(ii)  Reciprocal Inhibition in Dystonia
Although primary dystonia by definition does not present clinically with signs of 
corticospinal  or radicular dysfunction,  electrophysiological  testing  has  revealed 
deficits  in  spinal  reflex  control.  Compatible  with  the  original  description  of 
Nakashima et  al.195  in  non-genetically  characterised  dystonia,  spinal  reciprocal 
inhibition was normal in DYT1 patients in respect to the first phase of inhibition, 
however,  later  phases  were  reduced179.  Nonmanifesting  DYT1  carriers  had 
normal spinal reciprocal inhibition.179
e)  Summary of TMS Findings in Dystonia
In primary dystonia, both non-genetic and genetic forms, the overall impression 
is  of  an  over-excitablity  and  a  reduction  in  motor  inhibitory  circuit 
activity/function evident at many  levels  of the  nervous  system,  but most likely 
with  its  origins  in  the  basal  ganglia.  Secondly,  there  is  evidence  of abnormal 
plasticity in dystonia with increased susceptibility to undergo changes in synaptic 
effectiveness,  present  in  manifesting  patients.  Abnormal  plasticity  of  the 
sensorimotor system in dystonia is compatible with previous theories of dystonia, 
such  as  lack  of  “surround  inhibition”  {Mink,  2003  1878  /id;Sohn,  2004  770 
/id;Sohn,  2004  771  /id}  or  disordered  sensory  “gating”  of  movement.196  The 
subclinical  physiological  deficit  in  non-manifesting  carriers  are  not  as 
widespread as those seen in manifesting patients. Notably, non-manifesting gene 
carriers  appear  to  be  resistant  to  a  plastic  force  like  rTMS,  which  has  been 
interpreted  as  protective,  compensatory  mechanisms.This  would  be  consistent
71with the hypothesis that additional genetic/environmental insults are necessary to 
produce clinical dystonia in gene carriers.
Sensory system function is certainly not normal in dystonia, but it is still unclear 
whether this is a primary feature of dystonia or its consequence.  Abnormalities 
are  also present  in  non-manifesting  DYT1  subjects  and  may  represent  another 
form of endophenotype.
IV.  TMS in Genetic Myoclonus
1.  Definition and Classification Systems of Myoclonic Disorders
Myoclonus is characterized by a sudden, brief shock-like jerk due to involuntary 
contractions  (positive  myoclonus)  or  inhibition  of  muscular  tonic  contraction 
(negative  myoclonus).  Myoclonus  can  be  classified  by  etiology  which  may 
include degenerative, genetic, metabolic or other causes.
As  for genetic  forms  of myoclonus,  this  includes  the  big  group of progressive
myoclonic  epilepsies  (PME)  which  comprises  Unverricht  Lundborg  disease197
(due  to  mutations  in  the  cystatin  B  gene  EPM1  on  chromosome  21q22.3),
Lafora’s disease (due to mutation of the EPM2A gene on chromosome 6q24; or
EPM2B  gene  on  chromosome  6p22),  myoclonic  epilepsy  associated  with  red
ragged  fibres  (MERRF;  due  to  mutations  in  the  MTTK  mitochondrial  gene);
Sialidosis  (due  to neuraminidase  deficiency)  and DRPLA  (due  to  triplet repeat
expansion in the DRPLA gene).  In children presenting with the combination of
myoclonus  and  epilepsy  the  diagnosis  of juvenile  myoclonic  epilepsy  (JME)
should be considered. Although JME is mostly sporadic, a few genes have been
identified  for  this  genetically  hetereogenous  disorder  in  individual  cases.  This
72includes  mutations  in  the  GABRA1  gene,198  mutations  in  the  CACNB4,199 
mutations  in  the  chloride  channel-2  gene  (CLCN2)200  and  mutation  in  the 
GABRD gene.201 Other genetic causes of myoclonus include myoclonus dystonia 
due to mutations in the epsilon sarcoglcan gene which is discussed above under 
dystonic  syndromes  and  those  causing  a  more  complex  phenotype  with 
prominent dementia (e.g. Rett syndrome or Angelman syndrome).
Another  classification  system  of  myoclonus  disorders  is  by  anatomical  origin 
into  cortical,  subcortical,  brainstem  and  spinal  cord  myoclonus  or  myoclonus 
related  to  the  peripheral  nervous  system.  For  localization  of the  origin  of  the 
mycolonic jerks,  electrophysiological  techniques  can  be  helpful.  This  includes 
EMG studies, EEG studies with back-averaging of jerks and pre-movement EEG 
potentials, and SSEP recording.
TMS  data  are  overall  limited  for  myoclonic  conditions  and more  so for  those 
with  genetic causes. One reason for this may be that, as mentioned above, many 
of the genetic myoclonic syndromes manifest with epilepsy, and caution is to be 
used when these patients are studied and hence most centers may regard epilepsy 
as a contraindication for TMS.
2.  TMS in genetic Myoclonus
Few data are available on patients with PME and patients with JME.  However, 
none of the TMS studies assessed genetically proven cohorts of patients, but the 
diagnoses were made on clinical grounds. Aim of these studies was to distinguish 
between  different  clinically  overlapping  syndromes202  or  assess  effects  of 
antiepileptic treatment on electrophysiological measures." '
73a)  Single pulse TMS measures in Myoclonus
(i)  Thresholds in Myoclonus
Resting motor thresholds  were  normal  in patients  with JME.204,205  However,  in 
PME findings are more controversial  with  normal206 or increased thresholds.-07 
Such  increased thresholds may  be  a result of anticonvulsant  treatment and can 
also be found in patients with sporadic generalized epilepsy.
(ii)  Silent  Period in Myoclonus
206 Silent period has been reported normal in  12 patients with PME  and  patients 
with  JME205  as  opposed  to  shortened  CSP  in  myoclonus  syndromes  where
dementia  is  prominent  such  as  Angelman  syndrome,  Rett  syndrome  or
208 Corticobasal Degeneration.
b)  Paired pulse TMS Measures in Myoclonus
(i)  SICI,  LICI and ICF in genetic Myoclonus
At ISIs of 2-5  ms,  six  PME patients  showed either no or reduced inhibition.209
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This  is  in  line  with findings  in JME- -’  and non-genetic  forms of myoclonus 
(such  as  multifocal  cortical  myoclonus,  multifocal  and  bilateral  myoclonus, 
generalized cortical myoclonus;210 focal epilepsy and cortical myoclonus).211
However,  a  dissociation  between  PME and JME can  be  found with respect to 
long intracortical inhibition (LICI) which is normal in JME but reduced in PME. 
As mentioned above,  in both  these conditions,  CSP is normal. The dissociation 
of CSP and  LICI  in  PME  is  noteworthy  as  both  these  measures  are  tought  to 
reflect GABA B activity, (see Lefaucheur208 for review)
74The loss of inhibition was associated with the spread of myoclonus irrespective 
of whether epilepsy was present or not210 which may argue for partly different 
pathophysiological  mechanisms  underlying  mycolonic  bursts  and  epileptic 
discharges.208
ICF is normal in both JME and PME.204’205’207
(ii)  Short Afferent Inhibition in Myoclonus
In  PME,  a  subcortical  origin  of  the  myclonic  activity  has  been  suggested. 
Clinically,  myoclonic jerks can be triggered by stimuli including touch in PME 
patients  and  giant  somatosensory  evoked  potentials  can  be  detected  in  such 
patients.  Similarly,  abnormal  SAI measures  in  PME reflect the  involvement of
209 212 213 sensorimotor system.  ’   ’
In contrast, jerks cannot be elicited by audio or sensory stimulation in JME and 
here SAI is normal.  204
c)  Plasticity in Myoclonus
(i)  rTMS
Using low-frequency rTMS Fregni et aP *   found favorable results with reduction 
of myoclonus-related activity in  15 patients with JME and there was correlation 
with  plasma  valproate  levels  in  so  far  as  patients  with  low  levels  showed  a 
significant inhibitory effect to rTMS whereas in patients with high levels rTMS 
increased  the  corticospinal  excitability  significantly.  Single  cases  of secondary 
myoclonus  and  epilepsy  with  favourable  response  to  rTMS  have  also  been 
reported 214,215
75A long-latency response to peripheral stimulation and an exaggerated facilitatory 
effect  of peripheral  stimulation  on  the  motor  evoked  potential  was  present  in
” 719
subjects  with  PME,  suggesting  an  exaggerated  effect  of  afferent  input  on 
motor cortical excitability in PME.
d)  Summary of TMS in Myoclonus
Overall,  TMS  data  on  myoclonic  conditions  are  rare  (see  Lefaucheur"  for 
review);  more  so  in  genetic  myoclonus.  However,  it  appears  that  within  the 
group  of myoclonic  epilepsies,  PME may  cause  wider alterations  compared  to 
other forms.
It appears that myoclonus disorders with origin of the jerks on a cortical level are 
mainly  characterized  by  lack of inhibition  in  the  sense  of reduced  SICI,  while 
silent period measures are normal. The dissociation of CSP and LICI in PME is 
noteworthy as both these measures are tought to reflect GABA B activity. Low- 
frequent rTMS may be beneficial to reduce involuntary activity.
V.  TMS in Genetic Ataxia
1.  Clinical overview
The  term  ataxia  which  originats  from  the  Greek  word  for  "without  order"  (or 
incoordination)  refers  to  disturbances  in  the  control  of  body  posture,  motor 
coordination,  speech  control,  and eye  movements.  Genetic  forms  of ataxia  are 
classified into dominant,  recessive  and x-linked forms.  The  group  of dominant 
ataxias comprises among others  the  spinocerebellar ataxias  (SCAs)  and to date 
28 genetic  loci  have been detected or reserved.  Of these,  SCA6 is considered a
76“pure”  cerebellar  disorder,  whereas  the  other  genetic  SCAs  may  present  with 
other symptoms including movement disorders or neuropathy. A second group of 
autosomal  dominant  ataxias  entails  the  episodic  forms  type  I  (chromosome 
12p 13) and II (chromosome 19pl3).
The  group  of  recessive  forms  comprises  Friedreich  Ataxia,  Ataxia 
Teleangiectasia  and  its  phenocopies,  Ataxia  with  oculomotor aparaxia  I  and  II 
(due  to  mutations  in  aparataxin  on  chromosome  9pl3.3  and  senataxin  on 
chromosome 9p34), Ataxia with neuropathy I (SCAN1) and others.
2.  TMS in genetic ataxias
With respect to TMS, it is the common forms of ataxias which have mainly been 
investigated.  In  addition  to  several  historical  reports  based  on  clinical, 
histological  or  electrodiagnostic  diagnoses  (e.g  Cruz-Matinez  and  Palau  216), 
recent studies based on a molecular diagnosis have been published and these will 
be  reviewed  below.  Genetically-proven  cohorts  investigated  by  TMS  include 
SCA1,  2,  3  and  6  of  the  dominant  ataxias  and  the  recessive  syndrome  of 
Friedreich’s  Ataxia.  Other  genetically-proven  ataxia  syndromes  have  not  yet 
been studied.
a)  Single pulse TMS measures in genetic ataxia
(i)  Resting motor thresholds
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The  mean  resting  motor  threshold was  normal  in  seven  patients  with  SCA6“ 
with normal MEP recruitment curves.218 RMTs were also normal in SCA3.219
77^19 °20 In SCA1  reting thresholds were increased in the upper limbs,"  although the 
number of subjects was small (n=3) in one of these studies.
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In  SCA2,  resting motor  thresholds  were  normal.  However,  around  the  same 
time Restivo et a l221 reported significantly increased resting motor thresholds in 
the  lower  limbs  in  patients  with  SCA2;  whereas  no  differences  were  found  in
219 upper limbs, in line with the reports by Schwenkreis.
In  Friedreich’s  Ataxia,  some  authors  have  found  significantly  higher  mean 
phosphene threshold and motor threshold values in patients than controls which 
correlated  with  size  of  the  GAA1  expansion.222  Other  groups  found  normal
219 resting motor thresholds.
(ii)  Silent period in genetic ataxia
21 R
While ipsilateral silent period was normal in SCA6,  contralateral silent period 
was found significantly prolonged in these patients compared to controls.218
CSP  duration  in  both  arm  and  leg  muscles  was  significantly  longer  in  SCA2 
patients  (as  well  as  non-genetic  ataxia)  than  in  controls.221’223  There  was  a 
significant positive correlation between disease duration and CSP prolongation in 
SCA2 but no correlation between age, age at onset and CSP duration emerged.
Silent period measures were normal in SCA3 and Friedreich’s Ataxia.219
(iii)  CMCT in genetic ataxia
No  differences  were  found  in  mean  CMCT  as  tested  by  the  F-wave  method 
between  normal  controls  and  SCA6  patients.  217,219  Similarly,  normal  CMCT 
measures  were  found  in  SCA2  and  SC A3;  whereas  CMCT  was  prolonged  in 
SCA1  and  Friedreich’s  Ataxia.219,220  Clinical  measures  such  as  presence  of
78pyramidal  signs,  neuropathy  and  severity  and  duration  of  cerebellar  disease 
correlated with CMCT slowing.
b)  Paired pulse TMS in genetic ataxia
(i)  Short Intracortical inhibition and facilitation
In SCA6 and SCA1 both SICI and ICF were normal.219
In  SCA2  and  SCA3,  SICI  was  normal.221  However,  ICF  at  8,  10,  15  and 
20ms/30ms  was  reduced  in  SCA2  and  SCA3  at  all  intervals  which  correlated 
with disease severity in one of the studies 219,221
In Friedreich’s Ataxia, SICI and ICF were normal.219
(ii)  Short  afferent inhibition in genetic ataxia
In  SCA6,  both  short-latency  afferent  inhibition  and  long-latency  afferent 
inhibition were found normal.218
c)  Plasticity  of the nervous system in genetic ataxia
(i)  rTMS
A  small  study  (n=4)  investigated the possible  therapeutic effects of 5Hz rTMS 
over the cerebellum on clinical parameters in four patients with genetic ataxia.224 
Subjects  were  2  patients  with  SCA6,  one  patient  with  SCA1,  one  patient  with 
SCA7.  Ten  pulses  were  delivered over each  hemisphere  and  the middle of the 
cerebellum  on  21  consecutive  days.  Clincal  parameters  including  the  time
79required  for  walking  10  meters,  and  the  ability  to perform  tandem  gait  and  to 
keep body balance improved significantly. Other cerebellar signs like nystagmus, 
dysarthria  and  incoordination  remained  unchanged  after  rTMS  application. 
Blood flow increased in the cerebellar hemispheres, putamina and pontine base 
as demonstrated by SPECT.
Although  this  is  a  small  pilot  study  with  four  patients  only,  the  results  are 
beneficial and large studies would be interesting to investigate the effect of rTMS 
on genetic ataxia.
d)  Other TMS measures
(i)  F-wave amplitudes in genetic ataxia
F wave amplitudes, elicted by a supramaximal stimulus to the ulnar nerve, were 
normal  in  SCA6,  but significantly enlarged in  SCA1,  2 and 3  and Friedreich’s 
Ataxia.219
e)  Summary of TMS alterations in genetic ataxia
TMS  response  in relation  to the  underlying genetic  defect of ataxia  syndromes
(for example  the  subforms  of the  spinocerebellar ataxias)  have been studied by
some groups with a comprehensive study by Schwenkreis et al.219 This revealed 
that changes  of excitability  are not generally  present in  genetic  ataxias  but are 
restricted to some subtypes. rTMS data in genetic ataxia are limited to one small 
pilot study.
80Chapter 6  Methods
The experiments were approved by the ethics committee of the National Hospital 
and Institute of Neurology, London.
I.  Subject Ascertainment
Patients with Huntington's disease and young-onset PD due to parkin mutations 
were  ascertained  from  pre-existing  databases  of  patients  from  the  movement 
disorder clinics  at  the  National  Hospital  for Neurology  and Neurosurgery  who 
tested  positive  for  the  IT 15  and  parkin  mutation.  Inclusion  criteria  were  1) 
genetic analysis positive for the IT15  or parkin mutation,  2) no brain,  spinal or 
peripheral  nerve  surgery  in  the  past,  5)  no  history  of  other  neurological  or 
psychiatric  disease  other than  related  to  Huntington's  disease,  in  particular,  no 
history of epilepsy.
These  subjects  were  contacted by  telephone  and the  study  was  discussed  with 
them.  Subjects  who  expressed  interest  in  the  study  received  further  details. 
Participating  subjects  were  clinically  examined  and  disease  severity  rated 
according to the Unified Parkinson’s Disease Rating Scale (UPDRS) motor part 
III and the Unified Huntington’s Disease Rating Scale  (UHDRS)  scale.  Details 
on  patients'  age  at  onset,  response  to  treatment,  other  medical  history  were 
recorded.
Family  members  without  symptoms  had  previously  given  a  blood  sample  for 
mutation analysis on the understanding that no results of the gene anaylsis would 
be made available  to them.  Subjects  who wished to know  their gene test result 
were  refered  for  genetic  counselling  to  the  clinical  genetics  service  at  the 
National  Hospital  for  Neurology:  the  process  of counselling  and  delivery  and
81follow-up of these patients  was therefore performed separate from the  study as 
part of normal NHS clinical service provision. Subjects were informed that both 
mutation  positive  and  negative  subjects  would  be  invited  to  take  part  in  the 
elctrophbysiological studies, and therefore an invitation to take part should not be 
taken as evidence of mutation carriage.
In  practice,  many  asymptomatic  parkin  and  all  presymptomatic  HD  gene 
mutation  carriers  knew  their  mutation  status,  which  simplified  the  potential 
ethical dilemmas associated with this type of study.
1.  Recruitment of HD Subjects
We  recruited  a  total  of  16  subjects  with  a  molecular  genetic  diagnosis  of 
Huntington’s disease (for CAG repeat length  see table 7.1  (3 male,  13 female). 
We also recruited 22 healthy control  subjects  (13  male,  9 female)  with a mean 
age  of  36.1  years  (range  28-58).  HD  subjects  were  examined  clinically;  the 
UHDRS to score motor symptoms. Accordingly, eight patients were classified as 
pre-symptomatic  that  is  they  had  a  score  of  7  or  less  on  the  UHDRS  motor 
subscale as  well as no psychiatric  or cognitive  symptoms.  The remaining eight 
patients  were classified as early  symptomatic.  The  time  to  symptom  onset  was 
calculated according to Langbehn et al225.  Clinical  details of these patients  are 
given in table 7.1. Patients and controls were not taking medication at the time of 
the study.
822. Recruitment of Parkin Subjects
We studied eight genetically proven parkin patients (5male :3 female). Of these, 
six  were  compound  heterozygotes  and  two  were  homozygotes  for  the  parkin 
mutation.
Seven  genetically  proven  carriers  (4  male  :3  female),  all  parents  of  parkin 
patients were also studied. Five of these had participated in a previous  18F-dopa 
PET35  study  which  had revealed  mild  dopaminergic  deficits  in  the  caudate  or 
putamen in three of them. Characteristics of patients and carriers are summarized 
in Table 8.1.
Because  of  mean  age  differences  between  patients  and  carriers  two  different 
control  groups  were  studied;  one age-matched for the patients,  the  second age- 
matched  for  the  carriers.  No  participant  took  CNS  active  drugs  except 
dopaminergic  medication  which  was  withdrawn  prior  to  assessment.  Parkin 
patients  were  studied  "off'  medication,  meaning  they  withdrew  from  their 
dopaminergic  medication  for  12  hours  prior  to  TMS  assessment.  This  is 
compatible with half lives of the medication these patients were on, which were 
combinations  of  trihexyphenidyl  (half  life  3-4  hours),  levodopa  (half  life  of 
standard preparation 50 minutes and  1.5  hours when  taken with carbidopa) and 
ropinirole (half life 6 hours).
II.  Electrophysiological Methods
Different electrophysiological techniques were used in the experiments:
83TMS  Experiment  1:  TMS  biomakers  in  pre-symptomatic  HD  subjects 
and early disease HD patients compared to healthy controls:  assessment 
of thresholds,  input/output  curves,  intracortical  inhibition,  silent  period 
and short afferent inhibition. Results are described in Chapter 7
TMS  Experiment  2:  A  TMS  footprint  in  manifesting  and  non­
manifesting  parkin  subjects  compared  to  normal  subjects.  We  assessed 
thresholds,  input/output  curves,  silent  period,  central  motor  conduction 
time and intracortical inhibition and facilitation. Results are described in 
Chapter 8
These methods are described in turn below.
1.  TMS methods used in Experiment 1 and Experiment 2
Subjects  were  seated in  a  comfortable  chair with  their eyes  open.  EMGs  were 
recorded via Ag/AgCl electrodes placed over the first dorsal interosseous (FDI) 
using  a  belly-tendon  montage.  Signals  were  filtered  (30Hz-10KHz),  amplified 
(Digitimer 360, Digitimer Ltd., Welwyn Garden City, Herts, UK) and then stored 
on a computer via a Power 1401 data acquisition interface (Cambridge Electronic 
Design  Ltd,  Cambridge  UK).  Analysis  was  carried  out  using  Signal  Software 
(Cambridge Electronic Design).
TMS  was  delivered  on  the  hemisphere  contralateral  to  the  most  affected  body 
side  in  Parkin  patients  and  over  the  left  hemisphere  in  HD  patients  and 
asymptomatic  HD  and  Parkin  carriers  and  healthy  controls.  Magnetic  stimuli 
were  given  using  a  hand-held  figure-of-eight  coil  with  an  (outer  winding 
diameter 9 cm).  For single-pulse TMS the coil  was connected to a monophasic
84stimulator. For paired-pulse paradigms two magnetic stimulators were connected 
using  a  Y-shaped cable  (all  Magstim  Co,  UK).  The  optimal  spot  (“motor  hot 
spot”) was defined as the location on the scalp where TMS resulted consistently 
in the largest Motor Evoked Potential (MEP). For active measures subjects were 
asked  to  maintained  a  steady  background  contraction  of  about  20%  of  the 
maximum, as assessed visually on an oscilloscope. The following measures were 
performed:
a)  Motor thresholds (MT)
These  were  measured  at  rest  (RMT)  and  during  background  voluntary 
contraction  (AMT),  using  validated  criteria.226  MTs  mainly  reflect  the 
excitability of axonal membranes.
Resting motor threshold (RMT) was defined as the minimum intensity needed to 
evoke  an  MEP of >50/rV  in  5  out of  10 consecutive  trials  in  the relaxed FDI. 
Active motor threshold (AMT)  was defined as the minimum intensity  (in  %  of 
maximum stimulator output) needed to evoke a MEP of >200/xV in 5 out of 10 
trials  in  the  tonically  active  FDI  (-20%  of  maximal  contraction  as  assessed 
visually on an oscilloscope). Thresholds were approached from above threshold 
in steps of  1%  stimulator output.  Once no MEPs could be elicited the intensity 
was  increased  in  steps  of  1%  stimulator  output  until  a  minimal  MEP  was 
observed. This intensity was taken as motor threshold.
b)  Input/Output Curves of MEP amplitude
During  background  contraction,  10  MEPs  were  collected  at  each  stimulation 
intensity  starting  with  100%RMT and  increasing  stepwise  by  10%RMT  in  the
85Parkin experiment and by 25%RMT in the HD experiment up to  150%RMT of 
the  stimulator’s  maximal  output  while  the  patients  were  maintaining  a 
background  contraction  of  20%  of  their  maximum  power.  Ten  trials  were 
recorded,  and  the  average  MEP  area  was  taken  as  MEP  size.  For  amplitude 
measurements peak-to-peak values were averaged.
Recruitment  of  MEP  amplitude,  especially  in  the  active  state,  assesses  the 
amount  of  corticospinal  output  available  to  TMS.  The  gradient  of  the  curve 
provides  information regarding the distribution of excitability  within  the  whole 
motor neuronal pool.
c)  Central Motor Conduction Time during background 
contraction
In the Parkin experiment, central motor conduction time (CMCT) was assessed. 
Based on the recordings of the MEP recruitment curves, CMCT was calculated 
as  follows:  The  maximum  peripheral  delay  was  deducted  from  the  minimum 
MEP  latency  at  each  stimulation  intensity.  To  calculate  the  peripheral  delay 
spinal  roots  (C6/C7)  were  stimulated  at  150%RMT.  CMCT measures  provide 
information on the velocity of conduction within the corticospinal tract.
d)  Silent Period
As described above, the cortical silent period (CSP) is a period of EMG silence 
that  occurs  in  a  voluntarily  contracted  muscle  following  a  suprathreshold 
magnetic stimulation given over the contralateral representative motor area. CSP 
is  thought  a  measure  of  cortical  inhibitory  mechanisms  that  operate  during 
voluntary  contraction,  possibly  mediated  by  GABAe-ergic  circuits.  In  normal
86subjects duration of CSP is  typically  120ms,  although this can be  longer if the 
stimulation intensity is increased.95
In Parkin patients, CSP duration was measured at 130 and  140% RMT from the 
onset of the active MEP to the reappearance of uninterrupted EMG activity of a 
pre-stimulus mean amplitude. In HD patients, CSP duration was measured at 130, 
150 and 175% AMT.
The CSP/MEP AMPLITUDE ratio was calculated which is thought superior to 
absolute  measures  of CSP duration,  because  it  does  not depend  on  parameters
Q->
like coil  orientation  and the  stimulation  intensity  "  and the ratio represents  an 
additional measure of the inhibitory circuits underlying the CSP. In HD subjects, 
the area under the MEP was also determined.
e)  Intracortical Inhibition and Facilitation.
Ten  paired-stimuli  were  delivered  randomly  at  2,  3,  7,  10  and  15  ms  and 
intermixed  with  ten  single  test  stimuli.  In  parkin  studies,  the  conditioning 
stimulus (CS) was set at 80%AMT and the test stimulus (TS) at an intensity that 
produced  MEPs  of about  lmV.  Short  interstimulus  intervals  typically  result  in 
inhibition (SICI) and longer intervals in facilitation (ICF). Data from 2 and 3ms 
and from  7,  10  and  15ms  were  therefore  pooled and averaged to calculate  the 
amount of SICI and ICF respectively.  SICI and ICF were expressed as the ratio 
between  conditioned  and  unconditioned  trials.  In  HD  subjects,  ICF  was  not 
assessed.
f)  Recruitment Curve of SICI
In Parkin subjects,  SICI patterns were more thoroughly assessed by recruitment 
curves.  Paired  stimuli  were  delivered  randomly  at  different  conditioning
87stimulation (CS) intensities (70, 80, 90 or 100% of AMT) intermixed with single 
test  stimuli  (10  trials  per  condition).  The  test  stimulus  intensity  was  set  to 
produce  MEPs  of  lmV.  These  measures  provide  further  information  on  the 
excitability properties of the inhibitory intemeurons by assessing the change  in 
the amount of inhibition in respect to the CS intensity. Deepest inhibition usually 
occurs at 80-90%AMT CS.
g)  Short latency afferent inhibition by somatosensory input
from the median nerve
In HD subjects, we assessed short latency afferent inhibition of the motor cortex 
as  previously  described103.  A  test  MEP  of -lm V  peak-to-peak  amplitude  was 
elicited in the FDI by TMS. A paired pulse paradigm examined the influence on 
MEP  size  of  a  supra-threshold  electrical  stimulus  given  to  the  median  nerve 
through  bipolar  electrodes.  The  electrical  stimulus  to  the  median  nerve  was 
delivered at an intensity just above the threshold to elicit a visible contraction in 
the thenar muscles and preceded the TMS pulse to the FDI hot spot by  14,  18, 
20, 22, 24, 26 or 29ms. Twenty trials of the MEP elicited by TMS alone and  10 
trials  of conditioned  MEPs  for  each  ISI  were  collected.  The  amplitude  of the 
MEP in the FDI was measured with in-house software. The average amplitude of 
the conditioned MEP was expressed in percent of the average amplitude of the 
test MEP alone.
2.  Statistical Analysis
Data  were  collected  without  knowledge  about  the  clinical  status  or  disease 
severity of patients. Peak to peak amplitude of MEP, the area under the curve of
88the MEP and the silent period duration  were measured with in-house  software. 
All  statistical  analyses  were  performed  using  SPSS  11  for  Windows  software 
package. Statistical significance levels were set to p=0.05. Statistical differences 
in  the ANOVAs  were followed by a post-hoc paired t-test analysis.  Mauchly’s 
test was used to test for sphericity in the repeated measures ANOVAs,  and the 
Greenhouse-Geisser correction was applied to the DFs if necessary. Correlations 
of  the  CMCT  were  performed  using  non-parametric  tests  (Spearmann’s  rho 
correlation coefficient).
Parkin patients and carriers  were always compared to their corresponding  age- 
matched control group (referred to as “controls” only). When both control groups 
were compared they are referred to as younger controls and older controls.
The slopes of I/O curves at rest and during activity, the silent period recruitment 
and  SICI  recruitment  were  fitted  with  linear  regression  in  each  subject  Two 
factor ANOVA was used to compare groups with GROUP as in-between-subject 
factor.  The  second factor was  stimulation  intensity  with  the  different  levels  as 
applicable  (e.g.  100,  110,  120,  125,  130,  140  and  150%RMT  for  R C Mep  and 
R C cmct;  130% and  140%,  150% and  175% for CSP; 70, 80, 90 and  100%AMT 
for  R C sici  at  2ms).  Post-hoc  tests  with  Bonferonni  correction  were  used  when 
indicated.  For  CMCT,  95%  confidence  intervals  (95%CI)  of  the  CMCT 
distribution were calculated in controls and CMCT in patients  was  stratified as 
normal (within the 95%CI) or abnormal (outside the 95%CI).
Similarly,  for  paired  pulse  paradigms  repeated-measures  analysis  of  variance 
(ANOVA) was used to assessd ICI and ICF and whether there was a main effect 
of  ISI  on  MEP  size  or  conditioning  stimulus  intensity  (60,  70,  80,  90,
100%AMT) on the amount of SICI; or an effect of ISI on MEP size in the short-
89latency  afferent  inhibition  paradigm.  Because  inhibition  and  facilitation  at 
particular interstimulus intervals have different mechanisms, we grouped means 
at an “inhibitory” interval (average of 2, 3, and 4ms interstimulus intervals), and 
a “facilitatory” interval (average of 7, 10 and 15ms interstimulus intervals).
In order to assess how TMS parameters (RMT, SICI threshold, slopes of the I/O 
curve for MEP size at rest, maximum SAI) were associated with the estimate of 
time  to  onset  of  symptoms,  or  the  UHDRS/UPDRS  motor  score,  we  used 
backward stepwise regression analysis with  ‘years to onset’  or  ‘motor score’  as 
the  dependent  variable.  In  the  HD  experiment,  we  entered  ‘maximum  SAI’, 
‘CAG  repeat  length’  and  ‘age’  as  independent  parameters.  A  parameter  was 
removed from the model if the probability of its contribution was less then 0.1. 
MTs and age were compared using independent samples t-tests.
90Chapter 7  Results in HD Subjects
Details  of the  HD  participants  including  demographic,  molecular  genetic  and 
clinical data are given in Table 7.1.
Patient age gender CAG UHDRS motor
Years  to  predicted 
onset
Premanifest 1 41 F 43 0 10.59
Premanifest 2 39 F 42 2 16.10
Premanifest 3 40 M 41 4 19.10
Premanifest 4 32 M 40 0 33.54
Premanifest 5 28 F 47 7 10.50
Premanifest 6 38 F 40 2 27.68
Premanifest 7 38 F 40 1 27.68
Premanifest 8 53 F 41 5 9.44
Manifest 1 44 F 43 8
Manifest 2 48 M 47 16
Manifest 3 43 F 43 15
Manifest 4 33 F 44 13
Manifest 5 48 F 46 23
Manifest 6 37 F 43 8
Manifest 7 64 F 44 30
Manifest 8 40 F 46 30
Table  7.1:  Demographic,  molecular  genetic  and  clinical  data  from  HD 
patients. Predicted symptom onset was calculated according to Langbehn et
^25 al."  All premanifest patients had a diagnostic confidence score of less than
4 on the UHDRS.
91There was no significant difference in the mean age of HD subjects (41.6 years, 
range 28-64) and control subjects (36.1 years, range 28-58).
I.  Motor thresholds and motor cortex excitability at rest
Resting  motor  thresholds  of  all  patients  taken  together  (mean  43.4,  SE  1.7, 
95%CI 40-46.8) were higher than in controls (mean 38, SE  1.4, 95%CI 35.5-41) 
(ANOVA, main effect of ‘group’, Fi,36=5.57, p=0.024).
Dividing patients into the subgroups of premanifest (mean 42.6, SE 2.4, 95%CI 
37.8-47.5) and early manifest patients (mean 44.1, SE 2.4, 95%CI 39.3-49) there 
was still a trend towards higher RMT in patients than in controls (ANOVA, main 
effect of ‘subgroup’, p=0.07).
Thresholds with pre-activation (AMT) were also higher in patients (mean 33.2, 
SE  1.5  95%CI 30.1-36.2) than in controls (mean 28,  SE  1.2, 95%CI 25.5-30.5) 
(ANOVA,  main effect of ‘group’, Fi,36=7.04 p=0.012) even if dividing patients 
into premanifest (mean 32.8, SE 2.2, 95%CI 28.4-37.1) and early manifest (mean 
33.6, SE 2.2, 95%CI 29.3-38) (ANOVA, main effect of ‘subgroup’, F2,36=4.74, 
p=0.042).  Pairwise comparison  revealed  that  the  main  difference  was  between 
controls and early manifest patients (p=0.03) with a trend comparing controls and 
premanifest patients (p=0.065).
II.  Input/Output Curve
Above RMT, MEP size increased with increasing stimulation intensity (repeated 
measures ANOVA, main effect of ‘stimulation intensity’, F2,72=55.4, p<0.0001). 
However, patients recruitment slopes were flatter than those of controls (repeated
92measures ANOVA,  interaction  ‘intensity*group’,  F2,72=7.9, p=0.001) even with 
two  patients  subgroups  (repeated  measures  ANOVA,  interaction 
‘intensity *group’,  F2,72=3.9,  p=0.006,  Figure  7.1 A).  Post-hoc  pairwise
comparisons  showed  that  the  slope  of  both  premanifest  (0=0.013)  and  early 
manifest patients  (p=0.017)  was  flatter  than  in  controls  (Figure  7.1 A)  whereas 
the slopes of both patient subgroups were similar.
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Figure 7.1: cortico-spinal system excitability. A. MEP size recorded from 
relaxed FDI  after TMS  shock to the  Ml  hand area  with  110%,  125%  or 
150%  of  RMT.  Patients  recruitment  slopes  were  flatter  than  those  of 
controls  (repeated  measures  ANOVA,  interaction  ‘intensity^* group’, 
F2,72=3.9,  p=0.006).  Post-hoc pairwise comparisons  showed that the  slope 
of both  premanifest  (0=0.013)  and early  manifest patients  (p=0.017)  was
93flatter than in controls whereas the slopes of both patient subgroups were 
similar.  B-D. MEP size and CSP duration recorded from  active FDI after 
TMS shock to the Ml hand area with  130%,  150% or 175% of AMT. MEP 
area (B), CSP duration (C) and the ratio of CSP duration and MEP area (D) 
are similar in controls and HD patients. Values are means ±SEM, n=16 for 
HD patients (n=8 premanifest, n=8 early manifest), n=22 for controls.
III.  Motor cortex excitability with pre-activation and cortical silent 
periods
MEP size  (area)  increased significantly with  increasing stimulation intensity  in 
both  the  controls  and  the  patients  (repeated  measures  ANOVA,  F2,70=97.76, 
p<0.001,  Figure  7. IB).  This  increase  in  MEP  size  was  similar in  patients  and 
controls.  Cortical  silent  period  duration  also  increased  with  increasing 
stimulation  intensity  (repeated  measures  ANOVA,  main  effect  of  ‘stimulation 
intensity’, F2,70=136.3, p<0.001, Figure 7.1C) without major differences between 
patients and controls.  The  same was  true for the ratios of cortical  silent period 
duration and MEP area (Figure 7. ID).
IV.  Short interval intra-cortical inhibition
We distinguished between the threshold intensity needed to produce SICI and the 
amount of SICI at suprathreshold intensities of conditioning shock..227
First we determined the threshold for SICI as described previously '  which for 
technical reasons was not possible in one control and in two premanifest patients.
94SICI  thresholds  were  lower in  controls  (mean  17.9%,  SE  0.79,  95%CI  16.25- 
19.49)  than  in  patients  (mean  20.8,  SE  1,  95%CI  18.7-22.9)  (ANOVA,  main 
effect  of  ‘group’,  F2,34=5,  p=0.032).  This  effect  was  lost  when  patients  were 
divided into the premanifest and early manifest subgroups.
Above  threshold  increasing  the  conditioning  stimulus  intensities  reduced 
conditioned MEP size (repeated measures ANOVA, main effect of ‘conditioning 
stimulus intensity’, F2.56, 95.8=9 0 .1 5 , p<0.001, Figure 7.2). The recruitment slope 
was similar in patients and controls (repeated measures ANOVA, no significant 
interaction of ‘group*intensity’).
Figure  7.2:  Short  intracortical  inhibition  (SICI).  In  controls  and  patients 
increasing  intensity  of  the  conditioning  stimulus  reduced  the  size  of  the 
conditioned MEP in a similar way. Values are means ±SEM, n=14 for HD 
patients, n=22 for controls.
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95V.  Short latency afferent inhibition
In controls and patients, a supra-threshold electrical stimulus to the median nerve 
at  the  wrist  before  the  TMS  pulse  to  the  FDI  hot-spot  reduced  the  mean 
amplitude of the test stimulus predominantly at ISIs of 20, 22 and 24ms (repeated 
measures ANOVA, main effect of ‘ISI’, F2.34,84.3i=17.28, p<0.001, Figure 7.3).
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Figure  7.3:  Short  latency  afferent  inhibition  (SAI).  The  SAI  curve  was 
flatter  for  manifest  HD  patients  compared  with  controls  or  premanifest 
patients.
Since the early period of inhibition is more likely to have a partly cortical origin 
than later timings103 we assessed the maximum amount of afferent inhibition in 
each individual.  Maximal SAI was greatest in controls followed by premanifest 
patients and early manifest patients (ANOVA, main effect of ‘group’, F2,35=19.7, 
p<0.001, Figure 7.4). Post-hoc pairwise comparisons revealed that early manifest 
patients (mean 68.8, SE 5.5, 95%CI 57.6-80) differed from controls (mean 28.5, 
SE  3.3,  95%CI  21.8-35.3,  p<0.001)  and  premanifest  patients  (mean  37.15,  SE
965.5, 95%CI 26-48.3, p<0.001, Figure 7.4). Premanifest patients and controls were 
similar.
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Figure 7.4. Maximal SAI was greatest in controls followed by premanifest 
patients  and  early  manifest  patients  (ANOVA,  main  effect  of  ‘group’, 
Fz,35=19.7, pcO.OOl). Post-hoc pairwise comparisons revealed that controls 
and  premanifest  patients  had  more  SAI  than  early  manifest  patients 
(*p<0.001).  Values  are  means  ±SEM,  n=16  for  HD  patients  (n=8 
premanifest, n=8 early manifest), n=22 for controls.
VI.  Correlation of electrophysiological parameters and clinical measures
We  examined  whether  any  of  the  electrophysiological  parameters  were 
associated  with  the  presumed  disease  state.  Only  maximum  SAI  served  as  a 
predictor  for  estimated  years  to  motor  onset  (backward  stepwise  regression 
analysis  with  ‘years  to  onset’  as  dependent  variable,  ANOVA,  Fi,i3=8.2, 
p=0.013, R=0.61, R2=0.37, adjusted R2=0.32, Figure 7.5).
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Figure 7.5: Backward stepwise regression analysis. There was a significant 
correlation of max SAI with predicted years to onset of symptoms. Data are 
from 16 Huntington patients.
We  then  correlated  clinical  severity  (UHDRS  motor  score)  with 
electrophysiological parameters.
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Figure 7.6 Backward stepwise regression analysis. There was a significant 
correlation  of max  SAI  with  the  UHDRS  motor  score.  Data are  from  16 
Huntington patients.
Again, maximum SAI was the only predictor of UHDRS motor score (backward 
stepwise regression analysis with  ‘UHDRS motor score’  as  dependent variable,
98ANOVA, Fi, 13=15.63, p=0.001,  R=0.73, R2=0.53,  adjusted R2=0.5, Figure 7.6). 
Next, we examined for correlations of clinical severity with CAG repeat length, 
age and maximum SAI. This model strongly predicted the UHDRS motor score 
(ANOVA, F3,12= 1 1.4, p=0.001, R=0.86, R2=0.74, adjusted R2=0.68).
99Chapter 8  Results in Parkin subjects
Patients were significantly younger than carriers (p=0.003); their UPDRS motor 
score  was  35.3±11  (table  8.1).  Four  had  hyperreflexia  clinically.  11  healthy 
individuals (mean age 46.8±11.5 years) formed the “younger control” group; the 
group of “older controls” comprised of 10 healthy individuals (mean age 69.2±5 
years).
Clinical Phenotype Subject Age Age at UPDRS Hyper­ 18F-Dopa influx,  Ki  (min
onset score reflexia ’), in caudate; putamen
Manifesting  parkin 1/M ** 33 13 37 4- see  Khan  et  al.35  for  group
patients results
2/M  * 37 10-15 22 -
3/M  * 57 22 27 -
4/p ** 63 39 39 +
5/F  * 38 19 42 +
6/M  * 48 34 37 -
7/M  * 46 29 22 -
8/F  * 66 55 27 +
Asymptomatic parkin 1/M * 73 - 0 - 0.0146; 0.0136
heterozygotes
2/M * 63 - 0 - 0.0122; 0.0121*
3/F * 65 - 0 - 0.0094**; 0.0133
4/M * 64 - 0 - 0.0108**; 0.0126*
5/F* 69 - 0 - 0.0154; 0.0179
6/M * 66 - 0 - n.d.
7/F * 71 - 0 - n.d.
Means
Parkin patients 48.5±12. 35.3±11
Parkin carriers 66.5±3.4 0
Young  controls 46.8±11.5 0
(n= 11) 69.2±5 0
Old controls (n=10)
Table  8.1.  Demographic  and  clinical  characteristics  of  patients  and
asymptomatic  parkin  heterozygotes  (carriers).  *  heterozygote  for  parkin 
gene mutation;  **  homozygote for parkin gene mutation. #  1.5  SD below 
normals; ## 2 SD below normals; n.d. no data
100I.  Resting and Active Motor thresholds
Motor thresholds were the same in patients and controls (RMT: 40±6 vs 40±10, 
p=0.9, AMT: 34±5 vs 32±7, p=0.5) and between the two control groups. (Figure 
8.1). Carriers had significantly higher RMT (51±9 vs 40±7, p=0.015) and AMT 
(42±98 vs 32±4, p=0.03) than controls.
Motor Thresholds ■  Parkin patients
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Figure 8.1  Resting  and active motor thresholds for patients,  carriers  and 
control  subjects.  There was no difference between patients and their age- 
matched  controls.  Carriers  had  significantly  higher  RMT  and  AMTs 
compared to their controls.  The two control groups were not different.  *= 
significantly different from the corresponding age-matched group (p<0.05); 
RMT: resting motor threshold; AMT: active motor threshold.
101II.  Input/output curve
The inout/output curve during background contraction is demonstrated in Figure 
8.2.  A  two-factor ANOVA between  patients  and controls  showed a significant 
effect  of  SI  (F(4,68)=56.2,  p<0.001)  but  not  GROUP  with  no  SI  X  GROUP 
interaction.  Comparisons  between  carriers  and  controls  as  well  as  between 
younger  and  older  controls  yielded  similar  results.  This  indicates  that  all  the 
groups behaved similarly with increasing intensities of TMS.
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Figure  8.2:  Recruitment  of  active  MEPs.  There  were  no  significant 
differences in the recruitment of the active MEPs between patients and their 
controls or carriers and their control group. In all groups, the amplitude of 
the  active  MEPs  was  significantly  increased  with  higher  stimulation 
intensity.
III.  CMCT
CMCT was significantly longer in patients compared to controls. (Figure 8.3) A 
two-factor  ANOVA  showed  a  significant  main  effect  of  SI  (F(4,56)  =  11,
102pcO.OOl),  a significant SI X GROUP interaction (F(4,56)=5.7, p=0.007);  and a 
non-significant effect of GROUP (F(l,14) = 4, p=0.063). Subsequent one-factor 
ANOVA showed a significant main effect of SI in the controls (F(4,36) = 29.3, 
p<0.001);  CMCT  significantly  decreased  as  intensity  increased  and  in  most 
subjects reached a plateau at 120%RMT. In the patients there was no main effect 
of  SI;  i.e  CMCTs  did  not  change  with  increasing  SI;  pair-wise  comparisons 
revealed that patients  had significantly higher CMCTs compared to controls  at 
110%RMT (p=0.03),  130%RMT(p=0.006) and 140%RMT (p=0.01).
CMCTs  were  similar  between  carriers  and  controls  and  between  older  and 
younger controls.
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Figure  8.3.  Recruitment  of active  central  conduction  time  (CMCT): 
Patients  had  significantly  longer  CMCT  in  actively  contracting  muscles 
compared  to  their  age-matched  controls  at  110%RMT,  130%RMT  and 
140%RMT. Carriers had similar CMCTs to their controls. The two control 
groups  were  not  different  from  each  other.  In  the  carriers  and  the  two 
control groups CMCT was significantly shorter with increasing stimulation
103intensity. This was not seen in the patients. *  = significantly different among 
groups (p<0.05)
IV.  CSP duration
The CSP duration is shown in Figure 8.4. Two factor ANOVA on CSP duration 
showed  only  a  significant  main  effect  of  SI  for  all  comparisons  (patients  vs 
controls, carriers vs controls and between the two control groups). That indicates 
that all groups behaved similarly when the intensity was changed. When we used 
the CSP/MEP AMPLITUDE ratio for the analysis, again there was no difference 
between groups for all comparisons.
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Figure  8.4.  Absolute  duration  of  the  cortical  silent  period  for  patients, 
carriers  and  both  control  groups.  There  were  no  significant  differences 
between groups or within groups with increasing intensity.  RMT:  Resting 
motor threshold.
104V.  SICI /ICF
Rsults for SICI and ICF in Parkin patients and carriers compared to controls are 
depicted  in  Figure  8.5.  A  two-factor  ANOVA  between  patients  and  controls 
revealed a significant main effect of ISI (F(l,15)=83.5, pcO.OOl) with no effect 
of GROUP and no  ISI X GROUP interaction; thus, both groups showed similar 
values for SICI and ICF.
Comparing carriers  and controls,  ANOVA  showed a significant main effect of 
ISI  (F(l,14)=49.8,  pcO.OOl)  and  a  significant  main  effect  of  GROUP 
(F(l,14)=14.7,  p=0.002)  but  no  ISI  X  GROUP  interaction;  subsequent  t-tests 
showed that the GROUP effect was due to a non-significant tendency in carriers 
towards  reduced  SICI  (p=0.06).  Finally,  comparison  between  the  two  control 
groups showed a significant effect of SI (F(l,17)=94.04, pcO.OOl), but no effect 
of group or an interaction; suggesting similar SICI and ICF in younger and older 
controls.
SICI / ICF  ■   Parkin patients
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105Figure  8.5.  Short interval  intracortical  inhibition  (SICI)  and  intracortical 
facilitation (ICF).  SICI /ICF are expressed as percentage change from the 
mean test-MEP.
Patients and their controls had similar SICI and ICF; carriers tended to have 
reduced SICI compared to their control group, but this difference was not 
significant(p=0.06).  There  was  no  difference  between  the  two  control 
groups.
1.  SICI Recruitment Curve
The SICI recruitment curve at 2ms is shown in Figure 8.6. A two-factor ANOVA 
between  patients  and  controls  showed  a  significant  main  effect  of  SI 
(F(3,45)=6.5, p=0.004), but no effect of GROUP, nor a SI X GROUP interaction; 
subsequent  one  factor  ANOVAs  verified  a  main  effect  of  SI  in  patients 
(F(3,18)=5.4, p=0.008) and controls (F(3,27)=3.7, p=0.02). This suggests normal 
excitability in inhibitory circuits in parkin patients.
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Figure 8.6. Short interval intracortical inhibition (SICI) recruitment curve
at 2ms for patients, carriers and the two control groups. Patients and their
106controls had similar SICI: controls showed significantly stronger SICI at 
80%AMT and 90%AMT; in patients SICI was consistently stronger at 
80%AMT but not at higher stimulation intensities.
In  the  carriers  SICI fail  to  increase  with  increasing  stimulation  intensity. 
Compared  to  their  controls  there  was  a  significantly  reduced  SICI  at 
80%AMT  and  100%AMT.  There  was  no  difference  between  the  two 
control groups. * = significant difference between groups. (p<0.05)
Comparing carriers to controls, two factor ANOVA showed no effect of SI, but a 
significant effect of GROUP (F(l,13)=6.4, p=0.025)  together with a significant 
SI  X  GROUP  interaction  (F(3,39)=4.4,  p=0.01).  Subsequent  one-factor 
ANOVAs revealed that there was  no main SI effect in the carriers, i.e. SICI did 
not  change  with  increasing  stimulation  intensity;  compared  to  aged-matched 
controls carriers there was less inhibition at 80%AMT (p=0.015) and 100%AMT 
(p=0.02).  Finally,  comparison  between  both  control  groups  showed  that  both 
control groups had similar SICI recruitment.
VI.  Clinical correlations
Five  patients  (62%)  had  prolonged  CMCTs  (outside  95%CI);  there  was  a 
significant negative correlation between CMCT values and with onset age (rho= 
- 0.83, p=0.04), i.e. patients with early disease onset had longer CMCTs, but not 
with disease duration, UPDRS scores or presence of hyperreflexia.
107Chapter 9  Discussion
Here we used TMS to ascertain an electrophysiological footprint of patients with 
genetic movement disorders.
I.  Discussion of the findings in HD subjects
In the experiments we showed that patients with HD, both premanifest and early 
manifest, have higher motor cortex thresholds both at rest and in a pre-activated 
state.  SAI,  a measure of sensory-motor integration, is reduced in early manifest 
patients  compared  with  controls  and  premanifest  patients.  In  addition,  SAI  is 
inversely associated with predicted years to onset of HD signs and the UHDRS 
motor  score,  and  a combination  of age,  CAG repeat  length,  and  SAI  strongly 
predicted the UHDRS motor score.
Threshold measures depend on the excitability of axon membranes at the site of 
stimulation and the membrane potential of postsynaptic neurones in motor cortex 
and spinal cord. If the latter is depolarised then excitatory inputs are more likely 
to  cause  the  postsynaptic  cell  to  discharge  than  if  the  membrane  potential  is 
hyperpolarised.  During  active  contraction,  synaptic  excitability  is  high  so  that 
changes in threshold usually are thought to reflect changes in axonal excitability. 
The  fact  that  active  threshold  was  higher  in  HD  thus  suggests  that  axonal 
excitability  was  reduced.  At  rest,  threshold  will  also  depend  on  postsynaptic 
membrane  potential.  Whether  this  additionally  contributes  to  reduced  resting 
thresholds  in  HD  is  uncertain,  although  the  reduced  slope  of  the  resting 
recruitment  curve  would  be  compatible  with  additional  synaptic  effects. 
However,  these  electrophysiological  parameters  were  not  associated  with  the 
severity  of  patients’  motor  signs.  This  suggests  that  motoneurones  and  their
108modulation by inhibitory inter-neurones, i.e. the quality and shaping of the motor 
command, may not necessarily change as HD advances from the premanifest to 
the early manifest stage.
In  contrast  to  these  threshold  changes,  the  electrophysiological  measure  of 
inhibitory  interactions  of sensory  input  and  motor  output,  SAI,  was  related  to 
clinical  signs.  It  was reduced in early  manifest patients  but not  in  premanifest 
patients and showed an inverse relationship to UHDRS motor scores. Effectively, 
this means that once the balance of sensory input and motor output is disturbed, 
patients develop motor signs. Whether this is a causal connection or simply an 
association is unknown. However, the abnormalities in sensory-motor interaction
indicated by abnormal SAI may well be associated with the known reduction in
1  22
amplitude of somatosensory evoked potentials in manifesting individuals. 
Changes  in  the basal  ganglia and various cortical  areas  occur before  symptom
278 onset  in  HD.  These  include  the  formation  of  neuropil  aggregates,  “ 
oligodendrocytes,229  and  imaging  abnormalities230,231  including  focal  cortical 
thinning and pyramidal tract white matter abnormalities.232,233 Our results suggest 
that increases in axonal thresholds could be added to this list, and may also be an 
intrinsic reaction of the brain to the presence of the mutated huntingtin protein.
Mutated huntingtin probably confers not only a toxic gain of function but also a 
loss  of  function.234  Huntingtin  plays  an  important  role  in  neuronal
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development  * *   and life-long expression of mutant huntingtin may give rise to 
inherent  abnormalities  in  the  development  of  the  HD  brain.  Our  results  of 
abnormal  thresholds  could  alternatively  reflect  carrying  the  HD  mutation 
irrespective of whether the patient has motor manifestations rather than a result 
of a dynamic pathological process of HD.
109In  contrast,  our  measure  of  sensory-motor  integration,  SAI,  was  normal  until 
patients developed symptoms. It changed gradually over time such that together 
with  the  patient’s  age,  and  CAG  repeat  length  the  level  of  SAI  predicted 
symptom severity indicating this reflects the disease process rather than the HD 
trait. The SAI paradigm used in our study very likely involves cholinergic trans- 
synaptic pathways.  ’  Cholinergic abnormalities have been described in post­
mortem striatal tissue in HD239 and transgenic mice. 240 The striatum and cortex 
degenerate  most  in  the  course  of HD.241,242  Recent  evidence  indicates  cortical 
cholinergic changes precede those in the striatum.243 In premanifest patients this 
includes the pre-frontal cortex, an area relevant for sensory-motor integration.244 
Thus  our  data  suggest  a continuous  decline  of cholinergic  function  in  sensory 
inputs as the disease progresses similar to Alzheimer’s disease.245 In Alzheimer’s 
dementia SAI is also abnormal; interestingly in contrast to dementia with Lewy 
bodies where pathological changes are that of cortical Lewy bodies. A functional 
decline  in  cortical  cholinergic  function  may  be  due  to  a  loss  of  cholinergic 
synapses without neuronal cell loss243,246  and contribute to cognitive symptoms 
in HD patients and animals before motor onset.243 Cholinergic changes may be 
restricted to the cortex because the nucleus basalis of Meynert as the provider of 
most  of  the  cholinergic  cortical  input  does  not  degenerate  in  HD.247  These 
thoughts have also been outlined in the corresponding publication.
II.  Discussion of the findings in Parkin subjects
Parkin patients had prolonged CMCT, but normal motor thresholds and cortical 
inhibitory  activity.  Asymptomatic  carriers  had  increased  motor  thresholds  but
110CMCT  was  normal.  Additionally,  carriers  showed  abnormalities  in  SICI 
recruitment suggestive of changes in the excitability of the inhibitory circuits not 
seen in patients.
The  increased  CMCT  in  parkin  patients  confirms  the  report  by  De  Rosa  and 
colleagues130 in  a  smaller cohort of four parkin patients  at a  single  stimulation 
intensity.  Speculative causes for prolonged CMCT include demyelination of the 
corticospinal  tract,  loss  of  the  largest  fast  conducting  axons  in  the  tract,  or 
excessive synaptic delays at a cortical level in activating corticospinal fibers after 
the TMS pulse  is given.  Demyelination  seems unlikely given MRI  spine  scans 
were normal and demyelination should lead to greater increases of CMCT than 
the  2ms  seen here  as  well  as  smaller MEPs due to dispersion of impulses.  De 
Rosa and colleagues did report decreased MEP amplitude in one of their patients, 
but  our  results  in  a  larger  number  of  patients  do  not  confirm  this.  CMCT 
prolongation  therefore  may  reflect  changes  in  neuronal  properties  of  the 
pyramidal  cells  themselves  and/or  their  excitatory  intemeuronal  input  in  the 
cortex usually activated by TMS (I-wave inputs). In control subjects and carriers, 
increasing SI led to a decrease in CMCT. This effect, usually ascribed to direct 
activation of pyramidal axons at high TMS intensities (D-waves), rather than the 
usual indirect activation that occurs at lower intensities (1-waves),248’249 was not 
seen in patients. The combination of normal motor thresholds and normal MEP 
amplitude  suggests  that  CMCT prolongation  cannot  be  solely  explained  by  I- 
wave recruitment abnormalities, although this cannot be excluded without I-wave 
facilitation  studies.  It seems more  likely  that pyramidal  neuronal excitability  at 
high stimulation intensities (D-wave recruitment) is abnormal.
IllCMCT  was  normal  in  carriers  who  in  contrast  to  patients  had  increased 
thresholds. Thresholds are usually normal in PD and, if altered, they tend to be 
low.129 Thresholds were also normal in the  study by Baumer et al.131;  however 
their cohort was on average twenty years younger than ours.  (66.5±3.4 years in 
our study vs 40±1.2 in the study by 131) It is possible that these younger carriers 
may have higher thresholds were they to be tested twenty years later. Our finding 
would be compatible with the idea that it reflects  mild abnormalities  in  I-wave 
recruitment at low stimulation intensities. The different manifestations in patients 
and carriers could reflect the different disease load over time.
CMCT is normal in patients  with idiopathic  PD;  abnormally prolonged CMCT 
could question  the  diagnosis  of idiopathic  PD 250.  Thus,  CMCT measures  may 
represent  an  additional  tool  for the  identification  of parkin  disease.  Prolonged 
CMCT here may be associated with the hyperreflexia commonly seen in parkin 
patients.  Hyperreflexia  is  also  common  in  MSA  patients  who  also  show
250 abnormal CMCTs.  In this study we found no correlation between the presence 
of hyperreflexia and CMCT prolongation but this may be due to the small sample 
size. The significant relation with onset age may reflect pathophysiology but also 
requires confirmation with larger group sizes.
Our results for SICI and CSP suggest normal intracortical inhibitory activity in 
parkin patients.  CSP,  and more consistently  SICI,  have  been found reduced in 
idiopathic  PD,  especially  when  studied off medication.  However the finding is 
not specific since it occurs in several other movement disorders20'25’17927’31'33, and 
also does not correlate with disease duration or severity.251 The normal measures 
in  Parkin may reflect different underlying pathomechanisms and earlier disease 
onset  but  whether  the  physiological  profile  is  specific  for  parkin  associated
112parkinsonism  or  an  epiphenomenon  of  Mendelian  forms  of  parkinsonism  is 
unknown.
Like a previous study in carriers,13 1   we did not find significant abnormalities in 
SICI  .  However,  compared  to  age-matched  controls,  carriers  showed  reduced 
SICI recruitment with increasing stimulation intensity. Normally, SICI becomes 
evident at conditioning intensities around 70%AMT and deepens gradually as the
97 intensity  rises  to  80-100%,  after  which  it begins  to  turns  to facilitation.  It  is 
important  to  note  that  our  carriers  also  had  significantly  higher  AMT.  If  we 
hypothesize  that  the  threshold  of  the  SICI  intemeurons  does  not  increase  in 
parallel with that of the intemeurons mediating I waves (AMT),  the SICI curve 
would move to the right, and intensities of 90% or 100% AMT would fall outside 
the range  of inhibitory conditioning intensities  for SICI.  This is  well described 
for  stroke  and  studies  have  explored  increased  thresholds252  and  SICI  curves 
using absolute rather than relative stimulation intensities.  In our study SICI was 
significantly reduced on both ends of the curve suggesting that SICI recruitment 
abnormalities in carriers may not be just due to threshold differences.
One  possibility  is  that  SICI  reduction  represents  some  form  of  motor  cortex 
adaptation to compensate for the mild (subclinical) dopaminergic dysfunction in 
carriers.  In  a  recent  functional  imaging  study,253  changes  in  brain  activation 
associated  with  self selected  finger  movements  were  interpreted  as  adaptation 
allowing  carriers  to  maintain  motor  function  despite  subclinical  dopaminergic 
deficits.  A  similar  explanation  was  proposed  for  short  afferent  inhibition
1  * 5  1
alterations seen in the carriers.  Such adaptations presumably require synaptic 
modifications  in  the  cortex,  mainly  in  the  form  of  long  term 
potentiation/depression  (LTP/LTD),  and may  involve  modulation  of activity  in
113GABAergic  inhibitory  pathways.  SICI  is  thought  to  be  GABA-dependent. 
Finally,  such  compensatory  mechanisms  may  cease  to  operate  when  the 
underlying  deficit  exceeds  a  certain  threshold  and  overt  clinical  symptoms 
appear.  That  could  explain  why  SICI  abnormalities  were  not  present  in  our 
patients. One way to test this hypothesis would be to investigate the correlation 
between the severity and/or the distribution of the dopaminergic deficit and the 
changes  seen  in  cortical  physiology.  Such  an  analysis  would  require  a  larger 
cohort for whom both electrophysiology and imaging data are available.
Chapter 10  Conclusion
We  have  undertaken  experiments  in  manifesting  patients  and  pre-/non- 
manifesting gene mutation carriers with a representative autosomal dominant and 
recessive  disease  to  assess  the  usefulness  of  TMS  as  biomarker  for 
neurodegenerative  genetic  movement  disorders.  More  precisely  we  aimed  at 
assessing  whether  TMS  may  be  useful  1)  to  give  insight  into  underlying 
mechanisms  of the  disorders  studied;  2)  to  detect changes  early in  the  disease 
course and to monitor disease progression; and 3) to help differentiating between 
clinically similar diseases on the basis of certain electrophysiological patterns.
In  HD,  we  have  shown  that  TMS  is  perceptive  to  demonstrate  changes  in 
presymptomatic  gene  mutation  carriers.  It  is  known  that  changes  in  the  basal 
ganglia and various cortical areas occur before symptom onset.  This includes -  
as  we  have  now  shown  -  alterations  of  corticospinal  output  and  intracortical 
pathways including in patients with a predicted time to onset of up to 33 years.
114This  time  frame  exceeds  results  from  imaging  findings  where  the  process  of 
atrophy where changes were present 9 to 11 years prior to onset.254
We  have  furthermore  identified  SAI  as  a  marker  of  progression  of  the 
neurodegenerative  process  in  HD.  SAI  is  (still)  normal  in  pre-symptomatic 
disease  HD  subjects  but  becomes  abnormal  when  motor  symptoms  become 
overt.  There  was  an association with the  severity  of motor signs.  A regression 
model including SAI, CAG repeat length as the HD trait marker and age strongly 
predicted  symptom severity.  This makes  SAI  a possible potential  biomarker in 
HD. Of course this needs to be tested further in larger studies.
One  of  the  important  questions  with  respect  to  biomarkers  is,  how  well  the 
results are able to predict endpoints on an individual basis. This applies to two 
groups of individuals. First, does the biomarker allow to subdivide those “at risk” 
(offspring  who may  or may not carry  the  gene)  into carriers  and non-carriers. 
This  is important when children may not want to be  tested or in case of other 
inherited disorders for which the gene has not yet been identified. Second, does 
the  biomarker predict  outcome  and  progression  in  pre-mainfesting  individuals 
with  a  molecularly  confirmed  diagnosis?  Although  our  attempt  is  only  a  pilot 
study, the data suggest that SAI may be able to distinguish between carriers and 
non-carriers in that a maximum SAI greater than 55 or 60 is clearly abnormal and 
should raise the suspicion that the subject carriers the gene.  On the other hand, 
among the group of pre-manifesting subjects the group data suggest that there is 
progressive  worsening of SAI over time.  However,  one needs to  keep  in mind 
that there is  inter-individual  variability and it would thus be very interesting to 
study  the  same  subjects  using  the  same  parameters  to  look  for  the  degree  of 
progression of SAI abnormalities.
115Similarly,  in  Parkin,  TMS  detected abnormalities  not only  in  patients but  also 
asymptomatic  carriers.  The  latter  are  in  line  with  functional  and  structural 
imaging  studies  in  such  cohorts.  The  abnormalities  in  patients  correlated  with 
clinical  findings:  CMCT  was  correlated  to  age  of  symptom  onset.  We  also 
identified parameters  -  CMCT and  SICI  -  which  may  help  to distinguish  from 
idiopathic disease and to select candidates for genetic testing.
Furthermore, the TMS data allow some insights into the pathophysiology of the 
diseases. In HD, the abnormalities of SAI suggest problems with sensory-motor 
integration.  SAI  relies  on  cholinergic  trans-synaptic  cortical  pathways.  As 
outlined above, cholinergic abnormalities have been shown in post-mortem tissue 
and animal models and show similarities to Alzheimer’s disease.
In Parkin,  our experiments add to our understanding of the pathophysiology of 
recessive  Parkin-related  parkinsonism  in  that  compensatory  mechanisms  may 
play a part.
The review on TMS in genetic disorders has shown that most genetic conditions 
for which the gene has been identified have not been studied with TMS,  not to 
mention asymptomatic carriers. As a first further step in future studies, it may be 
interesting  to  more  thoroughly  assess  other  genetic  diseases  and  also  to 
investigate genotype-“electro-type” correlations; thus whether specific mutations 
are related to certain electrophysiological changes.
An intersting role of TMS is also in normal subjects in this respect as the genetic 
make-up  may  influence  not  only  electrophysiological  response  in  patients,  but 
also normals.127 We are currently exploring the role of BDNF on TMS reponse.
116^55 Furthermore, TMS may prove useful for the identification of endophentypes.“ 
Gottesman  and  Gould256  defined  endophenotypes  as  "measurable  components 
unseen  by  the  unaided  eye  along  the  pathway  between  disease  and  distal 
genotype".  They represent  "simpler clues to the genetics underpinning diseases 
than the disease syndrome itself'. Such electrophysiological endophentypes may 
guide future genetic studies and lead to identification of genes in families which 
are too small for classic linkage analysis or even in (so-called) sporadic forms of 
disease with low penetrance.
TMS  has  been  used  to  alter  behaviour  in  both  healthy  controls  and  patients 
including those  with genetic movement disorders (see chapter 5)  In addition to 
using  TMS  as  treatment  per  se,  it  may  be  interesting  to  see  whether  TMS 
response  may  correlate  with  response  to  treatment  or  even  predict  a  good 
outcome (e.g.  to predict surgical outcome of deep brain stimulation or response 
to oral medication).  In this regard,  we are currently studying the connection of 
genes-TMS-response  and  treatment-response  in  patients  with  Parkinson’s 
disease.
In summary, transcranial magnetic stimulation may be a useful biomarker as tool 
for  diagnosis  and  staging,  as  well  as  to  predict  and  monitor  response  to 
intervention  in  (genetic)  movement  disorders  and  other  neurological  disorders 
and deserves further investigation in the future.
117C)  Appendix 1: Summary of electrophysiological abnormalities in genetic movement disorders (Table 5.1)
Condition CMCT Threshol
d
MEP
Amplitude
CSP SICI ICF SAI RI Blink reflex
Parkinsonismus
Park2 Slower Higher  / 
normal
Increased  / 
normal
Shorter/
normal
Normal Normal
— — —
Park2 - carrier Normal Higher Normal Normal Reduced Normal Reduced
Dystonia
DYT1 Normal Normal Shorter Reduced Normal Absent
DYT1 - carrier Normal Normal Shorter Reduced Normal Normal
DRD Normal Normal Normal Controversial 
(Reduced  or 
normal)
Reduced  (no 
change  with 
treatment
Reduced (increased 
with treatment)
PxD Normal Normal normal Controversial 
(Reduced  or 
normal)
Normal Reduced
Myoclonus Dyst Increased Normal Normal
118Chorea
HD Normal Controver
sial
(normal or 
higher)
Controversia 
1  (reduced)
Prolonge
d
Reduced Controversial 
(reduced  or 
normal)
Reduced Reduced Abnormal (R2)
HD - carrier Higher Normal Normal Normal Reduced —-
—
Ataxia
SCA1 Slower higher  in
upper
limbs
Longer Normal Normal
SCA2 Normal Normal; 
higher  in 
lower 
limbs.
Longer Normal Reduced
SCA3 Normal Normal Normal Normal Reduced
SCA6 Normal Normal Ipsilateral
SP
normal; 
contralate 
ral  SP 
prolonged
Normal Normal Normal
Friedreich’s
Ataxia
Slower Controver
sial
— Normal Normal Normal — — —
119(normal or 
higher)
Myoclonus
JME Normal Normal Reduced Normal Normal
PME Normal/
increased
Normal Reduced Normal Paradoxi
cal
facilitati
on
Table 5.1 Summary of electrophysiological abnormalities in genetic movement disorders. CMCT, central motor conduction time; MEP, motor 
evoked potential; CSP, cortical silent period; SICI, short intracortical inhibition; ICF, intracortical facilitation; RI, reciprocal inhibition; carrier, 
asymptomatic / pre-symptomatic gene mutation carrier; DRD, Dopa-responsive dystonia; PxD, paroxysmal dyskinesias; Dyst, Dystonia; SCA, 
spinocerebellar  ataxia;  JME,  juvenile  myoclonic  epilepsy;  PME,  progressive  myoclonic  epilepsy
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